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Both placebo and distraction have long been used clinically to relieve pain. The present 
series of experiments examined the neural and cognitive processes that constitute these 
two psychological forms of analgesia. Study 1 provides evidence that overlapping cognitive 
resources are involved in both pain and executive attention and working memory. Study 2 
provides evidence that these same executive attention and working memory resources are 
not involved in placebo analgesia, and that placebo analgesia and distraction provide 
separate routes to pain relief. Study 3 suggests that while distraction-based analgesia 
reduces the neural signature of pain, expectancy-driven placebo analgesia may not.  
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Chapter 1: Introduction 
 
What is pain? 
The International Association for the Study of Pain (IASP) defines pain as “An 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage“ (Merskey & Bogduk, 1994). While this 
definition encompasses chronic, neuropathic and psychogenic pain, the present discussion 
will focus on acute, induced pain, as this type of pain is most relevant to the research 
presented in this dissertation. 
The IASP definition highlights the dual sensory and emotional nature of pain. Early 
philosophers including Aristotle and Plato did not classify pain as a distinct sensation, but 
rather saw pain as an emotional state accompanying the experience of strong sensations 
such as light, pressure or temperature (Dallenbach, 1939; Perl, 2007). This view was 
further elaborated by Erasmus Darwin in 1794 (Darwin, 2005),  and led to the intensive 
theory of William Erb, who argued in 1874 that pain could be generated by any sufficiently 
intense sensory stimulus (Dallenbach, 1939; Erb, 1874; Perl, 2007). In contrast, specificity 
theory argued that pain was a unique sensation relying on mechanisms distinct from those 
of other sensations like heat and touch (Dallenbach, 1939; Perl, 2007). First put forth by 
Avicenna in the 11th century (Avicenna & Gruner, 1930), this view was elaborated on by 
Descartes in the 17th century (Benini & DeLeo, 1999).  
While physiological and psychophysical evidence for both intensive and specificity 
theory were reported throughout the 19th century, by the early 20th century most scientists 
had come to support specificity theory (Perl, 2007).  However, specificity of pain as a 
sensation did not necessarily mean that pain could not have an emotional component. 
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Livingston argued in 1943 that fear and other-pain related emotions could produce 
descending excitation of pain-specific transmission fibers, resulting in positive feedback 
loops (Livingston, 1943). In 1968, Melzack and Casey put forth their influential three 
dimension theory of pain, which characterized pain as a combination of “sensory-
discriminative”, “affective-motivational”, and “cognitive-evaluative” dimensions (Melzack & 
Casey, 1968). Critically, the authors argued that pain was not simply a function of the 
intensity of the input stimulus, but also could be modulated by cognitive and affective 
factors. They noted that some cognitive factors, such as the excitement experienced in 
games or war, might modulate both affective-motivational and sensory-discriminative 
dimensions, while others, such as hypnosis or placebo, might exclusively impact the 
affective-motivational dimension. In conclusion, they urged clinicians and researchers to 
develop treatments for pain that relied on these affective-motivational and cognitive-
evaluative factors in addition to physiological treatments of incoming painful sensation.  
As is apparent in the IASP definition of pain, current thinking sees pain as a uniquely 
fused perceptual and emotional experience. Interestingly, current thinking also seems to 
favor a hybrid of the earlier intensity and specificity theories. While there is 
incontrovertible evidence for the existence of pain-specific nociceptors, there is also now 
strong evidence that parallel and convergent activity from other sensory modalities also 
plays a role in pain processing (Craig, 2003; Perl, 2007). In the following section, I will 
briefly discuss what is currently known about the functional neuroanatomy of pain, 
including a review of the ascending nociceptive pathways that travel from the periphery 
through the spinal cord and into the brainstem, and the network of brain regions that 




Functional neuroanatomy of nociception and pain  
The term nociception is used to describe the neural process of encoding noxious 
stimuli (Merskey & Bogduk, 1994). It is distinct from pain, which implies conscious 
experience, as indicated in IASP definition above. The distinction between nociception and 
pain is somewhat akin to the distinction between sensation and perception that has been 
made in other domains, such as vision.  Just as the physiological division between sensation 
and perception is not completely clear, neither is it clear exactly where in the ascending 
pain pathway nociception becomes pain. While pain and nociception typically co-occur, it is 
clear from these definitions that this need not always be so—nociception can occur without 
pain, and pain can occur without nociception.  In the following discussion, I describe a 
typical sequence of events that might follow the application of a thermal, peripheral, 
nociceptive stimulation that is experienced as painful, as this is case that is most germane 
to the present research.  
First, the hot probe will activate nerve endings in the skin called nociceptors (Snider 
& McMahon, 1998). Normally-functioning nociceptors only respond when a certain 
threshold is passed.  For most of the body, the cell bodies of nociceptors are located in the 
dorsal root ganglia, with only cell bodies of face nociceptors located instead in the 
trigeminal ganglia. Specific nociceptive transducers in the nerve ending determine whether 
it is capable of responding to a given stimulus. For example, the response to nociceptive 
heat is mediated in part by TRPV1 and TRPV2, proteins which respond to temperatures 
higher than about 43 °C and 52 °C, respectively, as well as capsaicin, the chemical in hot 
peppers, and low pH (Tominaga et al., 1998). Nociceptive information is conveyed by both 
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myelinated nerves, such as Aδ fibers, and unmyelinated nerves, such as C fibers.  The 
relatively fast transduction afforded by myelinated Aδ fibers leads to the sharp, initial part 
of the pain response, known as first pain, which typically drives the immediate impulse to 
pull away from an unexpectedly encountered burning stimulus. In contrast, slowly 
conducting C fibers are responsible for the dull, sustained burning sensation known as 
second pain (Craig, 2003).  
Both Aδ and C fibers cross the midline and enter the dorsal horn of the spinal cord. 
Typically Aδ fibers synapse in laminae I and V, while C fibers synapse in lamina II. Most 
nociceptive nerves then project up the spinal tract via the anterolateral system. The 
anterolateral system consists of three main pathways: the lateral spinothalamic tract, 
which projects to the thalamus; the spinoreticular tract, which projects to the reticular 
formation of the midbrain; and the spinomesencephalic tract, which projects to the dorsal 
midbrain (Tracey & Mantyh, 2007). Recent evidence also suggests that at least some 
ascending spinal neurons also project directly to the amygdala and hypothalamus (Willis & 
Westlund, 1997). 
Most nociceptive signals that reach the cortex do so via either the medial or lateral 
thalamus. The lateral thalamic projection involves relays in multiple nuclei of the ventral 
posterior region, including the ventral posterior lateral (VPL) and ventral posterior inferior 
(VPI) nuclei. Both nuclei contain somatotopically organized cells. VPL projects to the 
primary somatosensory cortex (SI), which is believed to be involved in spatial 
discrimination of pain perception, while VPI neurons are believed to project to secondary 
somatosensory cortex (SII), which is believed to be involved in affective components of 
pain (Willis & Westlund, 1997). In contrast, other projections target the intralaminar nuclei 
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of the medial thalamus. These neurons typically have been shown to have large, bilateral 
receptive fields, suggesting they are not important in spatial discrimination. However, they 
do discriminate between different levels of noxious heat. Historically, the medial thalamic 
pain relays have been thought to be primarily involved in motivational or affective 
responses to pain, but these findings suggest they may also play a role in the discrimination 
of intensity (Bushnell & Duncan, 1989). Some evidence also suggests that a somatotopically 
organized group of nociceptive cells project from the posterior portion of the ventral 
medial nucleus to the insula (Craig, Bushnell, Zhang, & Blomqvist, 1994), but the existence 
of this pathway remains under debate (Graziano & Jones, 2004).  
Although early researchers denied a role for the cerebral cortex in pain processing 
(Penfield & Boldrey, 1937; Penfield & Faulk, 1955), neuroimaging has identified a network 
of cortical and subcortical areas active during pain processing. Sometimes referred as the 
“neuromatrix” or “pain matrix” (Melzack, 1999), this network is widely thought to mirror 
the segregation of pain processing assumed for the thalamus,  with a lateral component 
preferentially involved in sensory-discriminatory pain processes, and a medial component 
preferentially involved in affective, evaluative, and cognitive pain processes (Tracey & 
Mantyh, 2007). A number of meta-analyses of pain neuroimaging results have been 
conducted (Apkarian, Bushnell, Treede, & Zubieta, 2005; Farrell, Laird, & Egan, 2005; 
Friebel, Eickhoff, & Lotze, 2011; Peyron, Laurent, & Garcia-Larrea, 2000; Salimi-Khorshidi, 
Smith, Keltner, Wager, & Nichols, 2009) and although the results differ somewhat across 
these analyses, the most reliably reported regions include SII, dorsal anterior cingulate 
cortex (ACC), insula, and thalamus.  
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Although these neuroimaging results clearly demonstrate cortical involvement in 
pain processing, neuroimaging results are inherently correlational, and thus they do not 
demonstrate that any of these regions are necessary or causal in the experience of pain. In 
that sense, they do not contradict Penfield’s early findings that stimulation of no cortical 
area reliably produced pain (Penfield & Boldrey, 1937; Penfield & Faulk, 1955). Modern 
electrical stimulation studies have largely replicated Penfield’s findings. For example, 
although painful stimulation elicits responses in neurons the human ACC, an area 
commonly seen in fMRI studies of pain, electrical stimulation of these same pain-
responsive neurons does not lead to the experience of pain (Hutchison, Davis, Lozano, 
Tasker, & Dostrovsky, 1999). However, using techniques that were not available to 
Penfield, a number of studies have reported that pain is induced by about 10% of the time 
following stimulation of deep areas of the parietal operculum and insula, indicating that 
these regions are causally involved in pain processing (Afif, Hoffmann, Minotti, Benabid, & 
Kahane, 2008; Mazzola, Isnard, & Mauguiere, 2006; Mazzola, Isnard, Peyron, & Mauguiere, 
2011; Ostrowsky et al., 2002). 
 
Distraction   
Distraction can be defined as the removal of attention from a particular mental 
representation and onto the source of the distraction. While distraction is often involuntary 
and unwanted, for example when a nearby conversation among colleagues draws one’s 
attention away from one’s work, it can also be intentional and desirable. For example, one 
might play a game on one’s phone to distract oneself from anxiety-producing thoughts 
while waiting for tests results at the doctor’s office.  
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Both medical professionals and lay people commonly use distraction to reduce pain. 
In fact, people prefer distraction to other coping strategies (McCaul & Haugtvedt, 1982; 
Wack & Turk, 1984), even when alternative strategies prove to be more effective (Ahles, 
Blanchard, & Leventhal, 1983). This widespread belief in its efficacy has led to extensive 
clinical and experimental research on distraction as a method of pain control (see Chapter 
2, Introduction, for a general discussion of previous research, and Table 2.1 for a summary 
of results in experimental, human studies published from 2000 to 2009). 
Why would distraction reduce pain? As I will discuss in greater detail below (see 
Chapter 2, Introduction), a limited-resources logic suggests that if pain is reduced by 
distraction, pain perception must involve effortful, non-automatic processes. This claim is 
consistent with previous theories, which have argued for the importance of cognition in 
mediating pain experiences (McCaul & Malott, 1984). It is important to note that while 
distraction-induced analgesia suggests that some pain processes relies on attention, it does 
not necessarily suggest that all pain processes are dependent on attention. For example, it 
might be the case that excess attentional resources allow one to think about pain, and 
thereby augment it. If so, removing these extra attentional resources might thus stop one 
from increasing one’s pain, but not reduce pain past a certain point. 
In recent years, several neuroimaging studies have examined the functional 
neuroanatomy of distraction-based analgesia (Bantick et al., 2002; Brooks, Nurmikko, 
Bimson, Singh, & Roberts, 2002; Frankenstein, Richter, McIntyre, & Remy, 2001; H. G. 
Hoffman, Richards, et al., 2004; Petrovic, Petersson, Ghatan, Stone-Elander, & Ingvar, 2000; 
Peyron et al., 1999; Ploner, Lee, Wiech, Bingel, & Tracey, 2011; Remy, Frankenstein, Mincic, 
Tomanek, & Stroman, 2003; Tracey et al., 2002; Valet et al., 2004). Taken together, these 
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studies indicate that distraction reduces activity in numerous pain processing regions, 
including medial thalamus (Bantick et al., 2002; H. G. Hoffman et al., 2011; Remy et al., 
2003), anterior insula (Bantick et al., 2002; Brooks et al., 2002; H. G. Hoffman et al., 2011; 
Remy et al., 2003), and ACC (Bantick et al., 2002; Frankenstein et al., 2001; H. G. Hoffman, 
Richards, et al., 2004; Remy et al., 2003). More limited evidence suggests that distraction 
may reduce pain-related activity in SI and SII (H. G. Hoffman, Richards, et al., 2004; Petrovic 
et al., 2000). 
An important question in this literature is whether these reductions in self-reported 
pain and activity in pain-processing regions occur as a result of general or specific 
mechanisms. For example, a general mechanism possibility is that, as a result of the 
resource-demanding task, otherwise available resources are tied up, and unavailable for 
competing nociceptive processes. In this scenario, the reduction of activity in pain 
processing areas is an indirect result of the activity supporting the distracting task. This 
activity could be observed with a contrast such as Distraction+Pain >No Distraction+Pain, 
but similar activity would be expected from a task-related contrast that did not involve 
pain, such as Distracting Task > No Task. Alternatively, specific source regions might come 
online when one performs a distracting task while experiencing pain that directly inhibit 
activity in pain-processing regions (Wiech, Ploner, & Tracey, 2008). If so, these specific 
processes would be observed by an interaction, for example of conditions such as Task 
(with levels of Task and No Task, or High Load Task and Low Load Task) and Pain (with 
levels of Pain and No Pain, or Painful Heat and Warmth).  
Several studies have found evidence of such “direct source” activity in midbrain 
periaqueductal gray (PAG; Remy et al., 2003; Tracey et al., 2002; Valet et al., 2004), 
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although at least one study found distraction-related decreases in PAG, an incompatible 
result (Petrovic et al., 2000). Other identified direct source regions include orbital frontal 
cortex (OFC; Bantick et al., 2002; Petrovic et al., 2000; Valet et al., 2004), perigenual ACC 
(Bantick et al., 2002; Valet et al., 2004), rostral prefrontal cortex (Remy et al., 2003), and 
dorsocaudal ACC (Remy et al., 2003). Several theories have suggested distraction-based 
analgesia may rely at least in part on descending nociceptive inhibition acting at the level of 
the spinal cord (Bingel & Tracey, 2008; Tracey & Mantyh, 2007; Wiech et al., 2008). One 
possibility is that these frontal cortical regions might directly invoke a PAG-mediated 
descending modulatory influence in order to protect task-related processing. One piece of 
evidence in support of this theory is that attending to a painful stimulus increases 
nociceptive responses in dorsal horn neurons in monkeys (Bushnell, Duncan, Dubner, & He, 
1984), and the nociceptive spinal flexion reflex in humans (Ruscheweyh, Kreusch, Albers, 
Sommer, & Marziniak, 2011), suggesting the involvement of descending nociceptive 
facilitation with attention. Two studies have also found distraction-related reductions in 
the nociceptive spinal flexion reflex in humans (Ruscheweyh et al., 2011; Willer, Boureau, & 
Albe-Fessard, 1979), though just as many have failed to detect a reduction, even though 
lower pain ratings indicated effective analgesia (Dowman, 2001; Terkelsen, Andersen, 
Molgaard, Hansen, & Jensen, 2004). The degree of distraction and the specific strategy used 
both seem to play a role in whether the spinal reflex is reduced (Ruscheweyh et al., 2011). 
Future work should seek to clarify the role of these parameters, and also to use 
hemodynamic imaging of the spinal cord, as has been done in placebo analgesia (Eippert, 




Placebo   
What is the placebo effect?  
A placebo treatment is one that is known to have no direct physical or 
pharmacological benefit for a given condition, such as a sugar pill given to a child to cure a 
stomachache. A placebo response occurs when conscious expectancies or conditioning 
invoked by the placebo treatment recruit endogenous physiological processes that reduce 
symptomatology. For example, the child likely believes in the power of medicines, and may 
have had previous pain-relieving experiences with pills. The reduction of symptomology 
itself—in this case, the alleviation of the stomachache—is described as the placebo effect 
(Atlas, Wager, Dahl, & Smith, 2009).  
Placebos appear to have been widely used and generally endorsed in medicine 
through the first half of the 20th century. However, they were generally thought to provide 
comfort to the patient, rather than to directly alleviate the medical condition under 
treatment (de Craen, Kaptchuk, Tijssen, & Kleijnen, 1999). Henry Beecher challenged this 
view in 1955 in his seminal article, “The Powerful Placebo”, which examined a range of 
published clinical trials and found surprisingly large effects of placebo treatments 
(Beecher, 1955).  
Although this article opened the door for serious scientific study of placebo, its 
conclusions were largely unfounded. In clinical trials, the goal is typically to test the efficacy 
of an intervention by seeing whether it can outperform a placebo control condition. 
Placebo control conditions in clinical trials are designed to mimic the experimental 
condition in every way, save for the specific, active component of the treatment. Despite 
their name, they are designed to control not just for placebo effects, but also for any other 
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effect or artifact that affect outcome of interest, including Hawthorne effects, spontaneous 
improvements, participant sampling bias, regression to the mean, and response bias. 
Hawthorne effects describe changes that occur simply as a result of being studied 
(Roethlisberger & Dickson, 1939). Spontaneous improvements might occur in any disease 
with a non-constant natural history. Regression to the mean describes the increased 
likelihood that a second sample mean will be closer to the population mean than the first 
sample mean if the first sample mean is far from the population mean. Participant sampling 
bias may increase the likelihood of observing spontaneous improvements, as patients 
might be more likely to enter a clinical trial when their symptoms are severe, leaving 
greater room for improvement due to natural symptom fluctuation and regression to the 
mean. Since placebo control conditions in clinical trials are designed to include all these 
potential influences, the clinical improvements that Beecher characterized as placebo 
effects could just as easily be attributed to any of them instead.  
To make a claim that clinical improvements are placebo effects, it is necessary to 
have a comparison condition that can control for these potential confounds and artifacts. 
Typically, experiments designed to study placebo itself accomplish this with a no treatment 
condition or an active control intervention that is explicitly not portrayed as treatment. For 
example, Hawthorne effects should be equal among the active control and placebo groups, 
so that the difference between the two should provide a pure measure of placebo. 
However, of the 15 studies included in Beecher’s original article, only two included no-
treatment control groups. In these two studies, the improvement in the placebo conditions 
was no greater than that in the no treatment control groups (de Craen, Kaptchuk, et al., 
1999). Thus, it seems that data used by this article to convince the scientific community 
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that placebos might have powerful effects could have more easily been used to downplay 
the power of placebos.  
Nonetheless, in the years since, many studies have found placebo treatments lead to 
greater symptom improvements than no-treatment controls. However, the comparison of 
placebo and no-treatment conditions is still susceptible to decision-related confounds, 
including response bias, demand characteristics and criterion shifts. These confounds 
involve changes in a measured dependent variable that do not reflect an actual change in 
the underlying construct of interest. Rather, they involve changes in the how the 
participant reports her experience. Thus, they typically only affect subjective measures, 
such as self-reported pain or depressive symptoms. Response bias occurs when a 
participant shifts her response in a way she believes will please the experimenter. For 
example, in the context of placebo analgesia treatment, asking a participant how much 
relief she felt, rather than whether she felt any relief at all, could unintentionally signal the 
hypothesis of the experiment to participant, potentially encouraging a more positive 
response. The overlapping concept of demand characteristics describes cases when 
participants form a belief, possibly unconscious, about the purpose of the experiment, and 
shift their responses to either confirm or disconfirm that hypothesis (Orne, 1962). Given 
that the purpose of a placebo manipulation is to instill in the participant the belief that the 
placebo intervention will relieve his symptoms and the control procedure will not, a 
placebo study is defined by unequal expectations and beliefs between the experimental 
conditions. Thus, the problems of response bias and demand characteristics cannot be 
resolved through a comparison condition.  
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Beginning in the 1960s, Crawford Clark attempted to resolve this problem by using 
Signal Detection Theory (SDT), a statistical framework which seeks to disambiguate signal 
sensitivity and bias (Tanner & Swets, 1954),  to analyze pain ratings in the context of 
placebo analgesia. Clark hypothesized that placebo interventions might not reduce actual 
pain experience, but instead simply change the criterion used by the participant when 
describing its intensity. In a series of studies, Clark found that SDT measures of pain 
sensitivity did not change as a result of placebo (Clark, 1969), suggestion (Clark & 
Goodman, 1974), or acupuncture (Clark & Yang, 1974), but measures of bias did, which he 
took as support of his hypothesis. In fact, these studies simply show that placebo 
treatments do not impair the ability of participants to accurately discriminate stimulus 
intensity. It is entirely conceivable that an individual might experience reduced pain 
without any loss in ability to discriminate signal intensity. Thus, these results are 
compatible with Clark’s hypothesis, but they do not disprove the competing hypothesis that 
placebo treatment produces analgesia. 
Given that response bias, demand characteristics and criterion shifts generally only 
affect self-report or other kinds of behavioral data that can be volitionally controlled, 
evidence for placebo effects free from these confounds can be found in studies which use 
dependent variables that are not subject to volitional control. For many medical conditions, 
objective measures are of primary interest. For example, in the treatment of throat cancer, 
while subjective measures of well-being are certainly important, the primary outcome 
measure is typically tumor growth. In contrast, other medical conditions, such as pain and 
depression, are defined by their subjective experience. In such cases, objective changes, 
such as reduced neural activity in brain regions associated with pain processing or negative 
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mood, are of minimal clinical value in the absence of changes self-report. Nonetheless, even 
when subjective measures are of primary clinical importance, objective measures provide 
crucial confirmation that placebo effects are not simply the result of decision-related 
confounds. 
Many studies have found placebo effects on objective measures, including bronchial 
hyperreactivity (Kemeny et al., 2007; but see also Wechsler et al., 2011), opioid and 
dopamine receptor availability (de la Fuente-Fernandez et al., 2002; Wager, Scott, & 
Zubieta, 2007), duodenal ulcer healing (de Craen, Moerman, et al., 1999), and 
hemodynamic response (Wager et al., 2004). However, a series of influential meta-analyses 
of clinical trials by Hróbjartsson and Gøtzsche found no evidence for placebo effects in 
studies in which objective dependent variables were used (Hrobjartsson & Gotzsche, 2001, 
2004a, 2004b, 2010). Notably, these meta-analyses did find placebo effects in trials using 
subjective outcome measures, such as pain report, leading the authors to conclude that 
reported placebo effects likely reflected only decision-related reporting biases. There are 
several possible reasons for this discrepancy between individual placebo studies and 
clinical trial meta-analyses. One possibility is that the positive findings of the placebo 
studies simply reflect chance compounded by publishing bias. This explanation is 
supported by analyses conducted by Hróbjartsson and Gøtzsche showing that, across 
studies, placebo effects diminished as sample size increased (Hrobjartsson & Gotzsche, 
2004a). However, as the number of publications demonstrating placebo effects with 




Alternatively, this discrepancy may reflect variability across medical conditions in 
susceptibility to placebo treatment. It may be the case that only a subset of maladies 
respond to placebos, and it is this subset that is addressed in placebo studies (Kirsch & 
Scoboria, 2001; Oh, 1994; Papakostas & Daras, 2001). In a follow-up re-analysis of the of 
the data used in Hróbjartsson and Gøtzsche (2001), studies were categorized by whether 
they were likely amenable to psychological factors (Wampold, Minami, Tierney, Baskin, & 
Bhati, 2005). Thus, insomnia, pain and depression were considered likely to be influenced 
to psychological factors, while anemia and bacterial infection were considered unlikely. In 
this analysis, studies of conditions deemed likely to be influenced by psychological factors 
showed robust placebo effects, while those deemed unlikely showed no effects. Although it 
seems that this distinction may have been confounded by the nature of the dependent 
variables, in that those studies with conditions deemed likely to be influenced by 
psychological factors also seem more likely to have used self-report measures, this 
possibility was discounted by a separate analysis that found no difference between 
subjective and objectively measured placebo conditions. Similarly, a separate meta-analysis 
of clinical trials found that “physical” dependent variables, such as blood pressure and 
expiratory volume, were responsive to placebo treatments, whereas “biochemical” 
dependent variables, such as cholesterol and cortisol, were not (Meissner, Distel, & 
Mitzdorf, 2007). In a follow-up analysis, these categories were validated on the dataset 
used by Hróbjartsson and Gøtzsche (2004a, 2004b). Clearly, an important future direction 
for placebo research is to delineate the conditions and physiological processes that are 
amenable to placebo interventions. 
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Finally, the discrepancy between the findings of placebo-specific studies and clinical 
trial meta-analyses may reflect relative differences in placebo-induced expectancies. There 
are several reasons to believe that placebo effects should be stronger in studies specifically 
designed to study placebo. In clinical trials participants are typically told from the outset 
that that may receive a placebo treatment, raising the possibility in the minds of the 
participants that they will not veridical treatment. Presumably, awareness of this 
possibility would decrease the expectation of relief, and reduce the placebo effect. In 
keeping with this hypothesis, Hróbjartsson and Gøtzsche (2010) found larger placebo 
effect sizes in studies in which participants were falsely informed that the placebo was a 
veridical treatment. In contrast, in studies designed to study the placebo researchers 
typically strive to convince the participant she is receiving a veridical and powerful 
treatment. Placebo studies may even include manipulation trials designed to associate the 
placebo treatment experience of relief. For example, in the context of a heat pain study, a 
topical analgesic might replace the placebo cream at first, or the applied temperatures 
might be covertly lowered. Manipulations such as these might strengthen expectations or 
even lead to unconscious conditioning in a placebo study, but would be expressly 
prohibited in a standard clinical trial. As such, it is not surprising that several meta-
analyses have found larger placebo responses in studies specifically designed to study 
placebo then in clinical trials (Hrobjartsson & Gotzsche, 2010; Vase, Riley, & Price, 2002). 
Of course, such findings may reflect publication biases. On the one hand, clinical trials are 
most likely to be published if they find small placebo effects, as the relative advantage of 
active treatment is likely to be greater, while on the other hand studies designed to 
examine placebo effects would likely only be published if placebo effects were found. 
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Nonetheless, taken together, these factors lend validity to the ever-growing number of 
studies reporting placebo effects in objective dependent variables, and suggest that placebo 
effects found using subjective measures are not simply the product of confounds such as 
response bias, demand characteristics and criterion shifts. 
 
Who responds to placebo treatments, and when?  
We have already noted several factors that likely determine whether placebo effects 
occur. Perhaps the most important is whether the condition under treatment is even 
amenable to placebo. Most theories of placebo predict that only a subset of possible 
medical conditions could potentially be improved by a placebo intervention (Kirsch & 
Scoboria, 2001). Specifically, pain, many psychiatric illnesses, disorders of the autonomic 
nervous system, and immunobiochemical conditions are considered to have the potential 
to be placebo-responsive, whereas hyperacute illnesses like heart failure, chronic 
degenerative diseases, and unremitting diseases, such hereditary syndromes, are unlikely 
to have to potential to respond to placebo (Meissner, 2011; Meissner & Ziep, 2011; Oh, 
1994; Papakostas & Daras, 2001; Wampold et al., 2005).  
Research has identified a number of other situational factors that also influence the 
likelihood or magnitude of placebo effects. In general, factors that increase the expectation 
of treatment efficacy appear to increase placebo effects. Perhaps the most straightforward 
way doctors communicate treatment efficacy is by talking to patients. One experiment 
found that a strongly-worded statement of an inert pill’s efficacy lead to greater pain relief 
than a weak message, which in turn lead to greater relief than no message at all (Gryll & 
Katahn, 1978). In placebo research, it is common to introduce the placebo intervention 
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with manipulation trials in which an active treatment surreptitiously and temporarily 
substitutes for the placebo treatment. Alternatively, experimenters might lower the 
stimulation level for the initial trials. In either case, the manipulation is designed so that 
participants come to associate the placebo intervention with reduced symptomology. In at 
least some cases, this association might constitute conditioned learning, and subsequent 
placebo effects might reflect unconscious conditioned responses (Amanzio & Benedetti, 
1999; Benedetti, Amanzio, Baldi, Casadio, & Maggi, 1999). However, most of the time these 
manipulations likely simply provide experiences of efficacy that serve to strengthen the 
expectation of future relief, rather than fostering conditioned learning per se (Price et al., 
1999).  
 The appearance and nature of the placebo delivery may also influence expectation. 
Several meta-analyses have found larger effects when more invasive procedures were 
used, such as sham acupuncture (Hrobjartsson & Gotzsche, 2010; Linde, Niemann, & 
Meissner, 2010). Similarly, treatment quantity has also been found to influence placebo 
magnitude. In one study, the level of activity participants reported after ingesting what 
they believed to be either a stimulant or a sedative scaled with whether they were given 
one or two pills (Blackwell, Bloomfield, & Buncher, 1972). More recently, a meta-analysis 
found that four placebo treatments per day more effectively healed duodenal ulcers than 
did two treatments per day (de Craen, Moerman, et al., 1999).  
Disease-specific treatment knowledge may also play a role in shaping placebo 
expectations. If one knows one’s illness is incurable, or that the intervention being 
described is medically implausible, one probably would not expect much from any new 
treatment, placebo or not (Cho, Hotopf, & Wessely, 2005). In support of this notion, one 
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meta-analysis found a positive correlation between the effects of placebo and active 
treatments across clinical trials (Moerman, 2000), suggesting a tight link between disease-
related knowledge, expectations, and placebo effects. More broadly, numerous studies have 
shown that how effective one expects a purported treatment will be predicts individual 
differences in the magnitude of placebo response (De Pascalis, Chiaradia, & Carotenuto, 
2002; Hyland & Whalley, 2008; Hyland, Whalley, & Geraghty, 2007; Price et al., 1999; Vase, 
Robinson, Verne, & Price, 2003; Whalley, Hyland, & Kirsch, 2008). In one study, expectation 
was manipulated by varying the magnitude of the reduction of painful heat during a 
conditioning phase (Price et al., 1999). The degree of reduction predicted both the post-
conditioning expectation of relief and the subsequent placebo effect. 
Context-specific individual differences in expectations may predict placebo 
responses, but what about enduring differences in personality? Such information could be 
useful in design clinical trials, as placebo responders could be potentially withheld from the 
sample or controlled for statistically, and it could be clinically useful, in that doctors 
seeking to use placebo treatments could target those most likely to respond. Many early 
studies trumpeted links found between personality and placebo responsivity, but these 
results often failed to replicate, and enthusiasm for such research waned (G. A. Hoffman, 
Harrington, & Fields, 2005; Kaptchuk et al., 2008; Shapiro & Shapiro, 1997; Turner, Deyo, 
Loeser, Von Korff, & Fordyce, 1994).  
There are several possible explanations for this surprising lack of success. One 
possibility is there simply might not be any particular personality that is responsive to 
placebo. Alternatively, early placebo researchers might not have looked at the right 
personality characteristics. Motivated by this possibility, recent years have witnessed a 
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wave of new studies reporting links between placebo and personality characteristics, 
including suggestibility (De Pascalis et al., 2002; Morton, El-Deredy, Watson, & Jones, 
2010), optimism (Geers, Kosbab, Helfer, Weiland, & Wellman, 2007; Geers, Wellman, 
Fowler, Helfer, & France, 2010; Morton, Watson, El-Deredy, & Jones, 2009), trait anxiety 
(Morton et al., 2009), behavioral drive (Schweinhardt, Seminowicz, Jaeger, Duncan, & 
Bushnell, 2009), fun seeking (Schweinhardt et al., 2009), and novelty-seeking 
(Schweinhardt et al., 2009), as well as other individual differences, such as motivation 
(Geers, Weiland, Kosbab, Landry, & Helfer, 2005) desire for relief (Vase et al., 2003). As of 
yet, none of these findings have shown robust replication, across multiple groups and 
paradigms, so more time will be needed to see whether this new wave of claimed 
personality-placebo links will revise the dominant current opinion that no specific placebo 
personality type exists.  
 Another possibility is that the question itself is flawed. Asking what personality 
factors predict placebo presumes that placebo-responsiveness is a stable and consistent 
trait within an individual. While a given placebo response appears to be relatively stable 
across multiple administrations (Morton et al., 2009; Whalley et al., 2008), several studies 
challenge the notion of a general placebo response tendency. In one early study, placebo 
response magnitude was found to be uncorrelated in a group of women exposed to three 
different types of pain (Liberman, 1964). In a more recent study, simply changing the brand 
name of the purported analgesic cream led to uncorrelated placebo responses (Whalley et 
al., 2008).  
One possibility is that certain personality characteristics may predict placebo 
effects, but only in specific contexts. Using the terminology of pioneering personality 
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researcher Walter Mischel, placebo responding may be a function of Person x Situation 
interactions (Mischel, 2004). At least some studies have found convincing evidence that 
such interactions may exist. For example, in one study, trait spirituality predicted placebo 
response to a spiritually-characterized “flower essence” placebo treatment, but not when 
the same treatment was characterized as non-spiritual (Hyland & Whalley, 2008). In 
another study, trait spirituality predicted placebo response to the flower essence 
treatment, but not to “gratitude therapy” for sleep problems (Hyland et al., 2007). 
However, trait gratitude did predict the response to gratitude therapy. Taken together, 
these results suggest that studies designed to detect Person x Situation interactions may 
provide a powerful resolution to some of the confusion that has plagued efforts to 
understand who responds to placebo treatments. However, the intra-individual variability 
in placebo response that has been seen as a function of subtle changes of context 
(Liberman, 1964; Whalley et al., 2008) suggests that such work will remain challenging. An 
important direction for future research will thus also be to more thoroughly explore the 
intra-individual variability of placebo responses across diverse placebo contexts.  
 
Functional neuroanatomy of placebo analgesia 
The following section focuses on the physiology of placebo analgesia, as it the most 
well-studied placebo domain and the most germane to the present research. In recent 
years, numerous PET and fMRI studies have examined the functional neuroanatomy of 
placebo analgesia (Bingel, Lorenz, Schoell, Weiller, & Buchel, 2006; Craggs, Price, Perlstein, 
Verne, & Robinson, 2008; Craggs, Price, Verne, Perlstein, & Robinson, 2007; Eippert, Bingel, 
et al., 2009; Eippert, Finsterbusch, Bingel, & Buchel, 2009; Harris et al., 2009; Kong et al., 
22 
 
2006; Kong et al., 2009; Lieberman et al., 2004; Lu et al., 2010; Petrovic et al., 2010; Price, 
Craggs, Verne, Perlstein, & Robinson, 2007; Scott et al., 2008; Wager, Atlas, Leotti, & Rilling, 
2011; Wager et al., 2004; Wager et al., 2007; Watson et al., 2009; Zubieta et al., 2005). 
Before reviewing the findings of this growing literature, it is important to consider the 
different roles that we can broadly assign to brain regions identified through different 
types of contrasts. A primary distinction can be made between target and source regions. 
Target regions are those in which pain-related activity is reduced. Target activity would be 
observed with a contrast such as Control>Placebo. Source regions are those in which 
activity increases during placebo. These are regions that might be important for initiating 
and maintaining the placebo response. Source activity would be observed with a contrast 
such Placebo>Control. It is also important to distinguish activity according to when it 
occurs. Activity can be measured during the stimulus period or during a pre-stimulus, 
anticipation period (Wager et al., 2011; Wager et al., 2004; Watson et al., 2009). Several 
studies have also broken up long pain periods, for example looking separately at early and 
late pain activity (Eippert, Bingel, et al., 2009; Wager et al., 2004).  
Looking across these studies, consistent source activity is seen in a number of 
frontal cortical regions, including bilateral dorsolateral prefrontal cortex (DLPFC), anterior 
PFC, OFC, and pregenual ACC (Wager & Fields, In press). While the exact roles of these 
regions in the placebo response is not known, one possibility is that they act as a circuit 
which generates and maintains expectations that lead to altered pain appraisals. This 
would be consistent with the established role of DLPFC in manipulating information in 
working memory (Smith & Jonides, 1999), and the OFC in generating and updating reward 
value and hedonic processes, and pregenual ACC in regulating emotional responses (Egner, 
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Etkin, Gale, & Hirsch, 2008; Etkin, Egner, Peraza, Kandel, & Hirsch, 2006; Sarinopoulos et 
al., 2010). Reliable activity increases have also been observed in PAG (Wager & Fields, In 
press). PAG is a critical relay in a descending pathway which interacts with ascending 
pathways to up- and down-regulate nociceptive processing (Heinricher, Tavares, Leith, & 
Lumb, 2009; Tracey & Mantyh, 2007). It may be that altered appraisals or expectations in 
frontal cortical regions directly invoke this PAG-mediated descending modulatory 
influence.  
Neural target regions that have been consistently reported include established pain-
processing regions, such as rostral dorsal anterior cingulate cortex, SII and SI, medial 
thalamus and anterior insula (Wager & Fields, In press). A central question in placebo 
analgesia research has been the level at which nociceptive processing is affected. One 
possibility is that placebo analgesia exclusively involves modulation of brain regions that 
are primarily involved in post-nociceptive aspects of pain, such as affect. This hypothesis 
seems to fit well with two aspects of the neuroimaging literature. First, the target regions 
that are most consistently observed appear to be the ACC and anterior insula, regions that 
are typically believed to be involved primarily in post-nociceptive aspects of pain. Second, 
several studies have found effects on pain-processing regions primarily during the latter 
portion of the pain stimulus, or even subsequent to it (Eippert, Bingel, et al., 2009; Wager et 
al., 2004). In contrast to the hypothesis that placebo analgesia is accomplished primarily by 
modulation of post-nociceptive pain processing regions, the gate-control theory posits 
brainstem-mediated regulation of ascending nociceptive processing in the brainstem and 
spinal cord (Melzack & Wall, 1965). Several findings provide support for the gate-control 
theory in placebo. One is the reliable activation of PAG in placebo, consistent with the 
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implementation of a descending modulatory influence, as described above. In perhaps the 
most striking support of gate-control theory, one recent study reported placebo-induced 
decreases of nociceptive activity in the spinal card (Eippert, Finsterbusch, et al., 2009). 
Importantly, the gate-control theory would imply reduction of post-nocicpetive pain-
processing activity as well. Thus, reduced activity in target regions in no way contradicts 
the gate-control theory. Taken together, these results suggest placebo analgesia arises at 
least in part from descending-inhibition of early pain-processing regions, but there may 
also be other effects that act on more-central, post-nocicpetive pain regions. 
 
  
     
Overview of the present research 
 
The present series of experiments examined the neural and cognitive processes that 
constitute distraction and placebo analgesia. Study 1 used the limited resources logic that 
when tradeoffs are observed between two concurrently performed tasks, it may be 
inferred that the tasks overlap in the mental resources they engage (Norman & Bobrow, 
1975). Results suggest that overlapping cognitive resources are involved in both pain and 
executive attention and working memory. Extending this limited resources logic, study 2 
provides evidence that these same executive attention and working memory resources are 
not involved in placebo analgesia, and that placebo analgesia and distraction provide 
separate routes to pain relief. Study 3 tested whether distraction and placebo analgesia 
reduce expression of a whole-brain, pain-predictive activity pattern. We found that while 
both distraction and placebo reduced pain reports, only distraction led to a widespread 







Chapter 2: Performance-dependent Inhibition of Pain by a Working Memory Task 
 
Abstract 
It is widely assumed that distraction reduces pain. Similarly, it is assumed that pain 
distracts from concurrent, unrelated cognitive processing, reducing performance on 
difficult tasks. Taken together, these assumptions suggest pain processing and cognitive 
function engage an overlapping set of domain-general, capacity-limited mental resources. 
However, experimental tests of this proposal have yielded mixed results, leading to 
alternative proposals that challenge the common model of a bidirectional relationship 
between concurrent pain and task performance. We tested these contrasting positions 
using a novel concurrent pain and executive working memory paradigm. Both task 
difficulty and nociceptive stimulus intensity were individually calibrated for each 
participant. Participants reported less pain during the working memory task than a visually 
matched control condition. Conversely, increasing levels of heat incrementally reduced task 
performance. Path analyses showed that variations in pain completely mediated this effect, 
and that even within a given heat level, trial-by-trial fluctuations in pain predicted 
decrements in performance. In sum, these findings argue that overlapping cognitive 
resources play a role in both pain processing and executive working memory. Future 
studies could use this paradigm to understand more precisely which components of 
executive function or other cognitive resources contribute to the experience of pain.  




It is commonly assumed that distraction reduces pain. Also common is the 
assumption that pain captures attention, reducing performance on difficult mental tasks 
(Eccleston & Crombez, 1999). Taken together, these assumptions imply a tradeoff between 
the experience of pain and goal-directed task performance (Legrain et al., 2009). When 
tradeoffs are observed between two concurrently performed tasks, it may be inferred that 
the tasks overlap in the mental resources they engage, and that the processing capacity of 
these resources is limited (Norman & Bobrow, 1975). Applying this logic to the tradeoff 
between performance and pain suggests the same executive resources that are believed to 
support goal-directed mental functioning may also play a role in the experience of pain.  
Extensive research has tested the common wisdom assumption that pain engages 
domain-general cognitive resources in non-human animals (Boyette-Davis, Thompson, & 
Fuchs, 2008; Bushnell et al., 1984; Casey & Morrow, 1983; Dubner, Hoffman, & Hayes, 
1981; Hayes, Dubner, & Hoffman, 1981; D. S. Hoffman, Dubner, Hayes, & Medlin, 1981), 
chronic pain patients (Dick, Eccleston, & Crombez, 2002; Dick & Rashiq, 2007; Glass & Park, 
2001; Harman & Ruyak, 2005; Oosterman, de Vries, Dijkerman, de Haan, & Scherder, 2008; 
Park, Glass, Minear, & Crofford, 2001; Scherder et al., 2008; Tassain et al., 2003; 
Veldhuijzen, van Wijck, et al., 2006), and healthy volunteers exposed to transient noxious 
stimuli (Bantick et al., 2002; Bingel, Rose, Glascher, & Buchel, 2007; Brooks et al., 2002; 
Coen et al., 2008; Crombez, Eccleston, Van den Broeck, Van Houdenhove, & Goubert, 2002; 
Dick et al., 2003; Dowman, 2004; Frankenstein et al., 2001; H. G. Hoffman, Richards, et al., 
2004; H. G. Hoffman, Sharar, et al., 2004; Houlihan et al., 2004; Kobor, Gal, & Vidnyanszky, 
2009; Lautenbacher, Prager, & Rollman, 2007; Petrovic et al., 2000; Pud & Sapir, 2006; 
Raudenbush, Koon, Cessna, & McCombs, 2009; Remy et al., 2003; Roelofs, Peters, van der 
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Zijden, & Vlaeyen, 2004; Schlereth, Baumgartner, Magerl, Stoeter, & Treede, 2003; 
Seminowicz & Davis, 2007a, 2007b; Seminowicz, Mikulis, & Davis, 2004; Terkelsen et al., 
2004; Valet et al., 2004; Van Damme, Crombez, Eccleston, & Goubert, 2004; Veldhuijzen, 
Kenemans, de Bruin, Olivier, & Volkerts, 2006; Wiech et al., 2005; Yamasaki, Kakigi, 
Watanabe, & Hoshiyama, 2000). We can distinguish these studies according to the explicit 
hypothesis tested (Fig. 2.1):  
I. Pain ratings or other indices of pain experience are reduced by unrelated, 
concurrent, cognitive demand; 




Fig. 2.1. Conceptual model of the relationship between pain and performance. Three general hypotheses can be tested to 
evaluate this model: I. Pain ratings or other indices of pain experience are reduced by unrelated, concurrent, cognitive 
demand; II. Cognitive performance is reduced by concurrent pain; III. A negative relationship exists between trial-by-trial 
fluctuations of performance and pain, even within a given heat level. 
 
Research in which healthy humans are exposed to transient pain balances the 
experimental control afforded by animal studies and the applicability and specificity 
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possible in research with chronic pain patients (Table 1). Looking at these studies in total, 
the results are surprising. While many found that participants reported less pain when task 
demand was greater (Bantick et al., 2002; Bingel et al., 2007; Coen et al., 2008; Dowman, 
2004; Frankenstein et al., 2001; H. G. Hoffman, Richards, et al., 2004; H. G. Hoffman, Sharar, 
et al., 2004; Kobor et al., 2009; Lautenbacher et al., 2007; Petrovic et al., 2000; Pud & Sapir, 
2006; Raudenbush et al., 2009; Remy et al., 2003; Schlereth et al., 2003; Seminowicz & 
Davis, 2007b; Terkelsen et al., 2004; Valet et al., 2004; Veldhuijzen, Kenemans, et al., 2006; 
Yamasaki et al., 2000), a large number found no effect of increased task demand (Houlihan 
et al., 2004; Pud & Sapir, 2006; Roelofs et al., 2004; Seminowicz & Davis, 2007a, 2007b; Van 
Damme et al., 2004). Furthermore, only a few studies have reported a decline in cognitive 
performance as a function of pain (Bingel et al., 2007; Crombez et al., 2002; Houlihan et al., 
2004), while most have found no effect (Coen et al., 2008; Dick et al., 2006; Dick et al., 2003; 
Houlihan et al., 2004; Kobor et al., 2009; Petrovic et al., 2000; Pud & Sapir, 2006; 
Seminowicz & Davis, 2007a, 2007b; Seminowicz et al., 2004; Veldhuijzen, Kenemans, et al., 
2006; Wiech et al., 2005). This paucity of supportive findings has given rise to alternative 
proposals that task demand does not reduce concurrent pain (Leventhal, 1992; McCaul, 
Monson, & Maki, 1992), that pain does not reduce concurrent performance (Veldhuijzen, 
Kenemans, et al., 2006), and that pain and goal-directed cognitive performance can occur 
simultaneously without meaningful interaction (Seminowicz & Davis, 2007a, 2007b). All of 
these proposals challenge the common model of a bidirectional relationship between pain 
and goal-directed cognitive performance.  
Alternatively, conceptual and methodological factors may account for the lack of 
support for the shared resources model found in the current literature (Devine & Spanos, 
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1990; Eccleston, 1995a). To discriminate among these competing models, we designed a 
paradigm to examine the relationship between pain and performance that accounted for 
several potentially confounding factors. Previous studies of the relationship between pain 
and cognitive demand have restricted their hypotheses to the level of experimental 
condition. However, the shared processes model would further predict a negative 
relationship between trial-by-trial fluctuations of performance and pain, even within a 
given heat level (pathway III in Fig. 2.1). A second goal of the current research was to test 
this prediction using a multilevel mediation framework. These analyses allowed us to 
further ask whether pain is a mediator of the heat level-performance relationship, which 











Table 2.1. Summary of literature since 2000 examining the relationship between experimentally-induced pain and 



































Bantick et al., 2002 [1] 8 Heat Counting Stroop NR Yes NR 
Bingel et al., 2007 [2] 16 Laser N-Back Yes Yes NR 





NR NR NR 
Buhle & Wager (present study)  24 Heat 3-back Yes Yes Yes 
Coen et al., 2008 [12] 12 
Esophageal 
Pressure 
1-back No Yes NR 




Tone Discrminiation Yes NA NA 
Dick et al., 2006 [16] 16 Pressure 
Auditory Oddball No NA NA 
Compatability No NA NA 




Subtraction NA Yes NA 
Frankenstein et al., 2001 [27] 10 Cold Pressor Word Generation NA Yes NA 
Hoffman et al., 2004 [33] 8 Heat Virtual Reality Game NA Yes NA 
Hoffman et al., 2004 [34] 39 Heat Virtual Reality Game NA Yes NA 
Houlihan et al., 2004 [35] 20 Cold Pressor Sternberg Mixed No NR 
Kobor et al., 2009 [39] 16 
Capsaicin 
and Pinprick 
Mental Rotation No Yes NR 
Lautenbacher et al., 2007 [40] 20 
Heat and 
Electrical 
Counting NR Yes NR 
Petrovic et al., 2000 [54] 7 Cold Pressor Maze No Yes NR 
Pud & Sapir, 2006 [56] 60 Heat 
Auditory 
Discrimination 
No Mixed NR 










Remy et al., 2003 [58] 12 Heat Word Generation NA Yes NA 
Roelofs et al., 2004 [59] 60 Cold Pressor Tone Discrimination NA No NA 
Schlereth et al., 2003 [62] 10 Laser Subtraction NA Yes NR 






No No NR 






Counting Stroop No Yes NR 
Emotional 
Distraction Stroop 
No No NR 




Counting Stroop No NA NA 
Emotional 
Distraction Stroop 
No NA NA 




Addition NA Yes NA 
Valet et al., 2004 [71] 7 Heat Stroop NR Yes NA 
Van Damme et al., 2004 [72] 99 Cold Pressor Tone Detection NA No NA 
Veldhuijzen et al., 2006 (exp 1) [74] 16 Cold Pressor                   No NA NA 
Veldhuijzen et al., 2006 (exp 2) [74] 12 Cold Pressor                   No Yes NR 
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1 "NA" indicates “Not applicable”, meaning the necessary conditions were not included in the experimental design. “NR” 
indicates "Not reported", meaning the necessary conditions were included in the experimental design, but the relevant 
analysis was not presented. 2. Within level of nociceptive input or task demand. 3. The effect of noxious stimulation on 
performance could be assessed for only 11 of the 18 participants, while the effect of task demand on pain could be 
assessed for entire sample. 4. Although several video game conditions were used, it is not clear that pain ratings were 
reduced in all conditions. 5. Personal communication with David Seminowicz, August 6, 2009. 
Table 2.1. Summary of literature since 2000 examining the relationship between experimentally-induced pain and 
concurrent, unrelated task demand in healthy adults. 
 
 
        
Method  
         
 Design. We designed a novel paradigm combining three levels of transient thermal 
pain with a 3-back executive working memory task. We chose the n-back paradigm 
(Kirchner, 1958) because of the high demand it places on central executive resources (Kane 
& Engle, 2002; Smith & Jonides, 1999). To ensure the 3-back was sufficiently challenging 
for each participant, we calibrated difficulty prior to the main experiment by adaptively 
adjusting the interval between probes. The allocation of executive resources in a given task 
reflects both task difficulty and contextual factors such as motivation (Legrain et al., 2009; 
Leotti & Wager, in press.). To increase motivation, participants were told that they could 
earn bonus money for good 3-back performance.  
 We compared pain in this demanding executive working memory condition to pain in 
the context of passively viewing a continuous letter mask, a baseline condition requiring 
minimal executive processes. In order to assure sufficiently high nociceptive input, we 
calibrated heat levels for each participant prior to the main task. We excluded participants 
who during this calibration procedure did not give pain ratings that corresponded reliably 
Wiech et al., 2005 (behavioral) [78] 11 
Capsaicin 
and Heat 
Rapid Serial Visual 
Processing 
NR Yes NR 
Wiech et al., 2005 (fMRI) [78] 15 
Capsaicin 
and Heat 
Rapid Serial Visual 
Processing 
No NA NA 
Yamasaki et al., 2000 [79] 11 Electrical 
Addition NR Yes NR 
Memorization NR Yes NR 
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with temperature or for whom we could not safely induce a high level of pain. For those 
individuals who remained in the study heat stimulation was only applied to the three most 
reliable skin sites out of eight initially tested. These procedures helped to substantially 
reduce within-participant variation. Finally, to obtain sensitive pain and performance 
measurements during the main experiment, participants rated each stimulus immediately 
after it occurred on a continuous rating scale, and 3-back responses were considered 
within a signal detection framework (Tanner & Swets, 1954; J. Zhang & S.T. Mueller, 2005).  
 All procedures were approved by the Columbia University Morningside Institutional 
Review Board.  
 
 Participants. Thirty participants began the experiment but five completed the 
calibration procedure with results that prohibited their continuation in the experiment: 
two participants were insufficiently sensitive to the maximum permitted temperature (48 
°C), while 3 participants were insufficiently reliable in their ratings across sites (R2 less 
than .5, as described below). One additional participant began the main experimental task 
but could not complete it on account of intolerable pain. Twenty-four right-handed 
volunteers (mean age: 25.0 years, range: 18.2 years to 43.5 years; 15 female) completed the 
experiment in its entirety and were included in analyses. All participants had normal or 
corrected-to-normal vision and were free of neurological and psychiatric illness. 
Compensation was given at a rate of $12 per hour. Participants were told they could earn 
up to $10 in bonus compensation for fast and accurate performance to enhance motivation, 
but in fact this additional $10 was given to everyone, regardless of performance. Most 
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participants completed the entire experimental session in 2 hours to 2.5 hours, resulting in 
total payment of $34 to $40. 
 
 3-Back Task. At the beginning of each trial, an on-screen message stated whether 
the current trial would require performance of the 3-back task or passive viewing of the 
serial letter mask. In the 3-back task, participants indicated whether each letter presented 
in a pseudorandom sequence was the same or different from the letter exactly three 
positions prior. The letters were presented centrally for 840 ms, subtending approximately 
0.7° visual angle vertically and 0.4° visual angle horizontally. Subsequent to the first three 
letters of a sequence, approximately 30% of letters were targets. Immediately after each 
probe letter a serial letter mask began. As described in greater detail below, for each 
participant a calibration procedure was conducted prior to the main experiment to 
determine a unique mask duration (mean: 698 ms, range: 104 ms to 1404 ms). Each letter 
in the serial letter mask was displayed for 26 ms. Participants pressed the “1” and “2” keys 
of the numeric keypad on a standard keyboard to indicate responses of “same” or “not the 
same”. Responses could be made any time during the presentation of the letter or the 
subsequent mask. The mapping of the keys was randomized across participants.  
 
 Rating Scale. During both the nociceptive calibration procedure and the main task 
(described in greater detail below), ratings were made on a visual analogue scale anchored 
with numbers from 0 to 8 and the following verbal descriptors: 0 was ‘‘no sensation’’; 1 
was ‘‘non-painful warmth’’; 2 was ‘‘just painful’’; 5 was “moderate pain”; 8 was ‘‘the 
maximum level of pain you are willing to experience here today”. Although pain intensity 
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and unpleasantness can be dissociated with specific instructions (for example, (Gracely, 
Dubner, & McGrath, 1979)), they are often highly correlated under normative conditions 
(Chapman et al., 2001). This scale was designed to integrate the two in a single intuitive 
rating. Although 8 was the largest number depicted on the scale, if the pain induced by a 
stimulation was greater than the maximum a participant was willing to tolerate in the 
experimental session, he or she was asked to rate the pain with a number reflecting how 
much greater the pain was than a level 8, up to a maximum of 10.  
 
 Procedure. The experimental session consisted of three distinct parts: nociceptive 
calibration, task difficulty calibration, and the main experimental task.  
 
Nociceptive Calibration. Nociceptive calibration involved 24 trials in which 
participants rated the pain induced by thermal stimulation (10 °C/s ramp up, 7 s at target 
temperature, 10 °C/s ramp down) applied using a 16 mm TSA-II Neurosensory Analyzer 
(Medoc Ltd., Chapel Hill, NC). Ratings were given verbally, and participants were told they 
were free to give non-integer ratings. Trials proceeded in a fixed order through 8 different 
candidate skin sites on the participants left forearm. On each trial after the initial three 
stimulations, an adaptive procedure was used to predict temperatures corresponding to 
pain ratings of 2, 5, and 8 (henceforth referred to as low, medium, and high). First, a linear 
regression model was fit with Temperature as the independent variable and Pain as the 
dependent variable. On the basis of this regression, trials were identified for which the 
absolute value of the residual was greater than the median of the absolute values of the 
residuals of all trials. A second regression was then performed in which Pain values for 
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these trials were replaced with predicted values from the first regression. The low, 
medium, and high heat level temperatures predicted by this second model were used to 
determine the temperature applied on the subsequent trial. A fixed, counterbalanced order, 
chosen to minimize predictive power, ensured one application each of a predicted low, 
medium and high temperature at each of the eight locations. Thus, the order of low, 
medium, and high trials was always the same, but the actual temperatures applied varied 
across trials and participants. If the predicted temperature for the heat level to be applied 
on a given trial was greater than the maximum permitted temperature of 48 °C, 48 °C was 
used instead. Participants were not told how the temperatures were determined or what 
they were. Following completion of the calibration trials, participants were excluded from 
further participation if the ratings they provided did not reliably correspond to the applied 
temperatures (R2 less than .5) or if the maximum permitted temperature of 48 °C did not 
induce sufficient pain (estimated pain rating less than 6.5). 
For 6 out of the 24 participants included in this analysis, the temperature estimated 
to correspond to a pain rating of 8 was greater than the maximum permitted temperature 
of 48 °C (max = 50.5 °C, mean = 49.1 °C, SD = .8 °C). For these participants, 48 °C was used 
as their final high heat level temperature in place of their estimated level 8. For all 
participants, the final heat level temperatures determined at the end of the calibration 
procedure were used for the duration of the experimental session (low: mean = 41.4, SD = 
2.0; medium: mean = 44.5, SD = 1.4; high: mean = 47.4, SD = .9). 
 
Task difficulty calibration. The second part of the experimental session was 
intended to familiarize participants with the 3-back task and to calibrate its difficulty. 
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Following written and verbal instruction, participants practiced the task in a short block of 
trials. Accuracy was indicated with a positive or negative sound immediately after each 
response. Participants were required to repeat this practice block if low performance 
suggested a lack of understanding, and were allowed to choose to repeat the practice block 
as many times as they wished. The calibration block consisted of 160 letter stimuli. Initial 
mask duration was 1000 ms. Prior to letter stimulus number 26, target sensitivity over the 
previous 15 stimuli was assessed with the nonparametric signal detection measure A (J. 
Zhang & S.T. Mueller, 2005), which provides a measure of performance accuracy 
independent of response bias (the tendency to report “yes” or “no” systematically). If 
sensitivity was higher than the targeted level of A = .75, mask duration was reduced by 200 
ms * (A-.75) * 4, while sensitivity equal or lower than A = .75 lead to an increase of 200 ms * 
(A-.75) * -4/3. Additional adjustments were made every 15 stimuli until all 160 stimuli 
were complete, yielding ten adjustments for each participant. 
 
Main task: Pain judgment and 3-back dual task. The third part of the 
experimental session consisted of 36 trials lasting about 50 s each (Fig. 2.2). Before each 
trial, the experimenter placed the thermode on one of the 3 skin sites identified as reliable 
during the nociceptive calibration. When ready, the participant pressed a key to begin the 
trial. An on-screen message indicated whether the current trial would require performance 
of the 3-back task (Working Memory Load trial) or passive viewing of the serial letter mask 
(No Load trial). On Working Memory Load trials, participants were cued to perform the 3-
back task for the next 39 s of the trial. On No Load trials, they were cued to maintain 
fixation on a continuous serial letter mask for the 39 s trial. Each participant performed 18 
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trials of each type over the course of the experiment; the assignment of task condition on 
each trial was randomized. On both Working Memory Load and No Load trials, after 13 s a 
tone indicated to the participant that noxious heat would be delivered. Heat onset began 
after a 26 s delay. The heat lasted for approximately 13 s, (2.1 s ramp up, 8.8 s target 
temperature, 2.1 s ramp down). Ramp rates ranged from 4.2 °C/s to 10 °C/s, depending on 
the target temperature. Unbeknownst to participants, only the temperatures determined at 
the end of the nociceptive calibration to correspond to the low, medium, and high heat 
levels were applied during the main task. In total, each participant performed 6 Working 
Memory Load and 6 No Load trials at each of the 3 heat levels.  
 
Fig. 2.2. Timeline of single trial. 
After 39 s, the temperature returned to baseline. On Working Memory Load trials 
the 3-back task ended at this point. For both Working Memory Load and No Load trials, the 
remaining portion of the trial was identical. After an additional 5 s of the serial letter mask, 
an onscreen rating bar appeared, along with the cue “how painful?” Participants were 
instructed to use the mouse to rate the pain they experienced during the heat stimulus by 
clicking anywhere on the rating bar that appeared on the screen, using the same anchors 
and following the same instructions as during the nociceptive calibration. After the rating 
was made following each trial, the experimenter then moved the thermode to the next skin 
site, after which the participant could begin the next trial whenever she was ready. To 
ensure the ratings given during the main experimental session were consistent with those 
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given during the calibration procedure, participants were given an opportunity to practice 
using the onscreen rating bar with feedback in a training procedure prior to the main 
experimental task.  
Unique letter and trial sequences were created for every participant and every trial 
with scripts written in MATLAB (version 7.5.0.342). Pseudorandom sequences were 
determined using the Mersenne Twister number generation algorithm (Matsumoto & 
Nishimura, 1998), with constraints to avoid long strings of identical letters and trial types.  
 
Mediation Analyses. A mediation framework was used to assess the hypothesis 
that trial-by-trial fluctuations in pain would negatively correlate with task performance. A 
test for mediation indicates whether a covariance between two variables (X and Y) can be 
explained by a third variable (M). A significant mediator is one whose inclusion as an 
intermediate variable in a path model of the effects of X on Y significantly affects the slope 
of the X – Y relationship; that is, the difference (c - c' ) is statistically significant. More 
formally, the mediation test can be captured in a system of three equations: 
Y = cX + e'Y 
M = aX + e M 
Y = bM + c' X + e'Y 
where Y, X, and M are n (Participant) by t (Trials) data vectors containing the outcome 
(either Y1, Performance, or Y2, Pain), the predictor (X1,2, Heat Level), and data from a 
candidate mediating variable (either M1, Pain, or M2, Performance). e Y, eM, and e'Y vectors 
denote residual error for the outcome and mediator controlling for x and the outcome 
controlling for x and m, respectively. The a path is the estimated linear change in M per X 
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(the slope of the Heat Level-Performance or Heat Level-Pain relationship). The b path is the 
slope of the mediator-outcome relationship controlling for x (Pain-Performance, or 
Performance-Pain, controlling for Heat Level). The c and c' paths are as described above. 
Statistical tests on a and b path coefficients assess the significance of each relationship. In 
addition, a statistical test of (c – c') can be performed by testing the significance of the 
product of the path coefficients ab. We tested the significance of ab using the accelerated, 
bias-corrected bootstrap test (Efron & Tibshirani, 1993) with 10,000 bootstrap samples to 
test each of the a, b, and ab path coefficients . Since the hypotheses contained explicit 
predictions of the direction of the relationships between variables (all negative except for 
the relationship between Heat Level and Pain), all tests were one-tailed.  
 
Results 
To test the hypothesis that task demand would reduce pain, we analyzed the data in 
a linear mixed effects model with Participant as a random-effects predictor, Task Demand 
(Working Memory Load or No Load) as a fixed-effects predictor, Heat Level as a 
continuous, fixed-effects predictor (low, medium, high), and Pain as the dependent variable 
(Fig. 2.3). A main effect of Heat Level indicated that higher levels of heat led to greater Pain, 
F(1, 768) = 281.82, MSE = 2934.89, p < .001, while a main effect of Task Demand indicated 
that greater demand led to lower Pain, F (1, 768) = 48.3, MSE = 166.73, p < .001. A main 
effect of Participant indicated that average Pain was different across individuals, F(23, 768) 
= 3.07, MSE = 10.61, p < .005. An interaction of Heat Level and Task Demand indicated that 
greater Task Demand reduced Pain by different amounts depending on the level of heat, 
F(1, 768) = 12.64, MSE = 17.45, p < .005. Post-hoc comparisons using Tukey’s honestly 
significant difference procedure confirmed that task demand reduced pain ratings at each 
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Heat Level (p < .05, corrected). A Participant x Task Demand interaction indicated that the 
magnitude of task-induced reduction in Pain varied across individuals, F(23, 768) = 3.45, 
MSE = 3.45, p < .05, and a Participant x Heat Level interaction indicated additional 
individual variability in the amount of Pain reported across the three levels of heat, F(23, 
768) = 10.41, MSE = 7.54, p < .001.  
 
Fig. 2.3. The effect of task demand on pain. Error bars reflect within-subject standard error computed using pooled 
variance from the Participant x Performance and Participant x Performance x Heat Level interactions [47]. 
A second mixed effects model tested the hypothesis that higher heat levels would 
reduce task performance (Figs. 2.4 and 2.5). Heat Level was entered as a continuous, fixed-
effects predictor and Participant was entered as a random-effects predictor. The dependent 
measure was Performance, assessed with the nonparametric measure of target sensitivity 
A. Only Working Memory Load trials were included in this analysis, as no performance data 
were available for the No Load trials. A main effect of Heat Level indicated that higher 
levels of heat led to lower Performance, F(1, 378) = 9.24, MSE = .130, p < .01, while a main 
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effect of Participant indicated that Performance varied across individuals, F(23, 378) = 
5.51, MSE = .157, p < .001. Post-hoc comparisons using Tukey’s honestly significant 
difference procedure indicated worse Performance at the high versus low level of heat, but 
no difference between the medium level of heat and the other two (p < .05, corrected).  
 
Fig. 2.4. The effect of heat level on performance. Error bars reflect within-subject standard error of the Participant x Heat 
Level interaction. The mean within-subject standard deviations of A were .14, .14, and .16 for low, medium, and high 
levels of heat, respectively. 
In order to test the relationships among heat level, pain, and task performance, we 
conducted two multilevel mediation analyses. The results of these are summarized in 
Figure 2.6. The first analysis assessed the hypothesis that trial-by-trial fluctuations in pain 
mediated the relationship between heat level and performance. We found that Pain fully 
mediated the relationship between Heat Level and Performance (ab= -.03, Z = -3.91, p < 
.001). In addition to the significant mediation (ab) effect, there was a significant, positive 
effect of Heat Level on Pain (a = 2.07, Z = 4.22, p < .001), and a negative effect of Pain on 
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Performance, controlling for Heat Level (b = -.02, Z = -3.52, p < .001). Although there was a 
strong positive relationship between Heat Level and Performance (c = -.02, Z = -3.35, p < 
.001), after controlling for Pain, this relationship was no longer significant (c' = .02, ns), 
indicating that Pain was a complete mediator.  
 
Fig. 2.5. The relationship between pain and performance. For visualization, performance data were binned into quintiles 
based on pain ratings. 
A second mediation analysis assessed the complementary hypothesis that trial-by-
trial fluctuations in performance mediated the relationship between heat level and pain. 
We found that Performance partially mediated the relationship between Heat Level and 
Pain (ab = .01, Z = 1.77, p < .05). In addition to the significant mediation (ab) effect, there 
was a significant, negative effect of Heat Level on Performance (a = -.02, Z = -3.36, p < .001), 
and a negative effect of Performance on Pain, controlling for Heat Level (b = -2.16, Z = -3.61 
p < .001). After controlling for Performance, a direct relationship remained between Heat 




Fig. 2.6. Summary of mediation results for Working Memory Load trials. A first mediation analysis assessed whether Pain 
(M1) mediated the relationship between Heat level (X1) and Performance (Y1): a1: the relationship between Heat Level 
and Pain; b1: : the relationship between Pain and Performance, controlling for Heat Level; c1: the observed relationship 
between Heat level and Performance; c´1: the relationship between Heat Level and Performance, controlling for a1 and b1. 
A second mediation analysis assessed whether trial-by-trial fluctuations in Performance (M2) mediated the relationship 
between Heat Level (X2) and Pain (Y2): a2: the relationship between Heat Level and Performance; b2: the relationship 
between Performance and Pain, controlling for Heat Level; c2: the observed relationship between Heat Level and Pain; c´2: 
the relationship between Heat Level and Pain, controlling for a2 and b2. * p< .05. **p< .001. 
 
Discussion 
Previous research has typically assumed a bidirectional relationship between pain 
and task performance (Legrain et al., 2009), implying both engage an overlapping set of 
domain-general, capacity-limited cognitive resources. Yet experimental evidence has been 
equivocal, leading to alternative proposals (Leventhal, 1992; McCaul et al., 1992; 
Seminowicz & Davis, 2007a, 2007b; Veldhuijzen, Kenemans, et al., 2006). We sought to 
distinguish between these competing views using a novel paradigm designed to place 
continuous demand on executive processes and sensitive, trial-level analyses. Participants 
reported less pain during a difficult 3-back working memory task than a visually matched 
control condition. Conversely, increasing levels of heat incrementally reduced task 
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performance, and trial-by-trial pain reports predicted performance within a given heat 
level. Using a mediation framework, we found that accounting for these trial-by-trial pain 
reports fully explained the relationship between heat and performance. In a separate 
mediation analysis, we also found that trial-by-trial performance in the task partially 
explained pain reports. Taken together, these findings suggest that the processes that 
contribute positively to both pain and executive working memory performance share 
capacity-limited resources (Legrain et al., 2009). Furthermore, resource allocation varies 
from one process to the other over time, so that observed variation in each predicts effects 
on the other. That is, better performance on a given trial predicts lower pain, and higher 
pain predicts worse performance. Though our mediation analyses are consistent with the 
notion that each causally influences the other, follow-up experiments that independently 
manipulate both pain and task performance experimentally are needed to solidify causal 
inferences. 
A shared resources model of pain and cognitive performance is consistent with 
several neuroimaging meta-analyses that found reliable pain-related activity in lateral and 
anterior PFC (Peyron et al., 2000; Salimi-Khorshidi et al., 2009). These regions have been 
strongly implicated in diverse executive processes (Wager & Smith, 2003), and activity in 
them has been shown to increase parametrically with demand in an number of executive 
tasks (Braver et al., 1997; Cohen et al., 1997; Durston et al., 2003; Jonides et al., 1997; 
Szameitat, Schubert, Muller, & Von Cramon, 2002; Veltman, Rombouts, & Dolan, 2003). 
However, the few previous studies that have directly examined the effects on PFC activity 
of incremental changes in pain have found activation with painful stimulation, but not 
incremental changes of activity that tracked increases in stimulus intensity or reported 
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pain (Bornhovd et al., 2002; Buchel et al., 2002). One possible explanation for this 
difference is that PFC activity may not provide a sensitive index of resource limitation 
across levels of pain. For example, PFC may be activated under both weak and strong 
noxious stimulation, but for different reasons. At low levels of stimulation, PFC might be 
recruited to reappraise pain or allocate attention elsewhere, consistent with previous 
studies that suggest a pain-regulatory role (Lorenz, Minoshima, & Casey, 2003; Valet et al., 
2004; S. Zhang, J. S. Tang, B. Yuan, & H. Jia, 1997; Zhang, Tang, Yuan, & Jia, 1998; Y. Q. Zhang, 
J. S. Tang, B. Yuan, & H. Jia, 1997). Conversely, at high levels of stimulation, greater PFC 
activity might reflect increased generation of pain-related cognitions or allocation of 
attention towards pain. This account predicts that the PFC-pain relationship may be 
moderated by the intensity of noxious stimulation: it should be negatively correlated with 
pain at low stimulus intensity and positively correlated with pain at high stimulus intensity. 
Other explanations that need to be tested are also possible, including: (a) BOLD activity 
may show a ceiling effect, because PFC is strongly engaged by even weak noxious stimuli; 
(b) as pain increases, individuals may shift toward alternate coping strategies that do not 
recruit lateral PFC; and (c), PFC may be recruited to resolve ambiguity and enhance 
discrimination under weak stimulation, but to regulate pain during intense stimulation. 
Interestingly, these latter two alternatives imply moderation effects opposite to our initial 
explanation above, yielding divergent empirical predictions.  
The affirmative findings of the present research again raise the question of why 
some studies have observed interference between pain and cognitive performance while 
others did not (Table 2.1). Comparing these studies suggests several technical and 
conceptual factors may be critical to observing this relationship, including the type and 
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intensity of task demand and the degree of temporal overlap between task and pain 
processing (see also discussions in (Eccleston, 1995a; Seminowicz & Davis, 2007b)). 
Specifically, we posit that the task must substantially and continuously demand executive 
resources. While we did not test this hypothesis in the current research, several aspects of 
the experimental design reflect this assumption. First, we chose a task that places heavy 
demands on executive working memory and that has been well characterized both 
theoretically and neurally. N-back performance requires both the continuous updating of 
representations in working memory and response selection (Wager & Smith, 2003). An 
earlier study similarly found that concurrent n-back performance reduced pain (Bingel et 
al., 2007). However, consistent with the view that executive demand is critical for a task to 
interfere with pain processing, another study that used the Sternberg task, a working 
memory task that places relatively little demand on executive function, found no reduction 
in pain during task performance (Houlihan et al., 2004). Interference tasks and other 
Stroop-like tasks also engage executive processes (Miyake et al., 2000), but current results 
from interference tasks are mixed: pain reduction was reported with a standard Stroop 
task (Valet et al., 2004) and with numeric Stroop task variants (Bantick et al., 2002; 
Seminowicz & Davis, 2007b), but not when the challenging Multisource Interference Task 
was used (Seminowicz & Davis, 2007a). Several other studies found a task-related 
reduction in pain using paradigms that are less well characterized in the literature, 
including maze performance (Petrovic et al., 2000), visual search (Veldhuijzen, Kenemans, 
et al., 2006), arithmetic (Dowman, 2004; Schlereth et al., 2003; Terkelsen et al., 2004; 
Yamasaki et al., 2000), word generation (Frankenstein et al., 2001; Remy et al., 2003), 
video and virtual reality games (H. G. Hoffman, Richards, et al., 2004; H. G. Hoffman, Sharar, 
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et al., 2004; Raudenbush et al., 2009), mental rotation (Kobor et al., 2009), detection and 
discrimination (Brooks et al., 2002; Crombez et al., 2002; Pud & Sapir, 2006; Roelofs et al., 
2004; Van Damme et al., 2004), and rapid serial visual presentation tasks (Wiech et al., 
2005). Because it is less clear which component processes these tasks require, at present 
these findings cannot be used assess the hypothesis that executive demand is critical. 
Furthermore, tasks which should place minimal demand on executive resources have 
yielded mixed results: while an emotional distraction counting Stroop task variant (Buhle, 
Wager, & Smith, in press.) had no effect on pain (Seminowicz & Davis, 2007b), a simple 1-
back task successfully reduced pain (Coen et al., 2008). Future research will need to 
explicitly compare different types of demand within a single experiment in order to 
provide a rigorous test of the role of executive demand in pain reduction. 
A second choice was to calibrate task difficulty. Our goal was twofold. First, we 
sought to ensure the task would yield a measure sufficiently sensitive to detect a 
deleterious influence of pain on performance for each participant. If the task is not 
sufficiently demanding, then painful stimulation may only transiently and subtly interrupt 
task performance. Modest decrements in performance will only be detectable if 
participants are performing near capacity and performance measures are sensitive. Second, 
we sought to ensure that successful performance of the task would require a profound 
commitment of executive resources (Eccleston, 1995a). Even tasks that engage executive 
function may not interfere with pain if they do not place a heavy demand on information 
processing.  
A third choice we made was to motivate participants with a monetary reward for 
good performance. Our intention was to ensure the greatest possible dedication of 
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resources to the task. Unmotivated participants might perform at a lower level sufficiently 
below their ability, leaving idle resources available for concomitant pain processing 
(Legrain et al., 2009). However, given the possibility that reward processing may interact 
with pain (Leknes & Tracey, 2008), future research should confirm that motivated 
performance of a demanding task can reduce pain regardless of reward context.  
Even if pain and task processing engage overlapping executive resources, if this 
engagement does not overlap in time, participants would be able to switch attention back 
and forth between pain and cognitive demand, allowing both to be fully processed 
(Eccleston, 1995b; Veldhuijzen, 2006; Veldhuijzen, Kenemans, et al., 2006). Thus, a fourth 
choice we made was to combine continuous thermal pain with a speeded n-back task that 
placed relatively continuous demand on executive working memory. In contrast, when 
Seminowicz and Davis (Seminowicz & Davis, 2007a) combined relatively continuous 
electrical pain with the relatively brief and interspersed processing demands of the 
Multisource Interference Task, no reductions in pain or performance were observed.  
  Future studies could directly test the hypotheses we offered to explain the 
inconsistent previous findings. For example, the criticality of executive demand could be 
examined by directly comparing the pain reduction incurred by executive working memory 
tasks such as the n-back with working memory tasks which only involve storage, such as 
the Sternberg task (for more on this distinction, see (Wager & Smith, 2003)). Future 
research could also examine whether different types of executive function, such as 
perceptual attention demand and executive working memory, influence pain differently 
(Lavie, 2005). A third important goal for future research would be to clarify the role of pain 
duration. We hypothesize that brief shock or contact heat will cause intermittent and minor 
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disruption of task performance on response selection, such as a Stroop task, but more 
profound disruption of tasks that require temporal continuity, such as a difficult n-back. 
Furthermore, brief noxious stimuli with rapid onsets may capture attention even in the 
context of a challenging cognitive task.  
In sum, these findings support the view that subjective pain and executive working 
memory performance engage overlapping, capacity-limited cognitive resources. 
Furthermore, reciprocal variation in pain and performance within a given heat level 
suggests these limited resources are dynamically allocated between the two processes. 
Future studies could use the paradigm and analyses we present here to more precisely 
identify which cognitive resources participate in pain processing and to illuminate the 
specific roles they play. 




Chapter 3: Placebo and Distraction: Two Distinct Routes to Pain Relief 
 
Abstract          
An explosion of recent research has studied whether placebo treatments influence 
health-related outcomes and their biological markers, but almost no research has examined 
the psychological processes required for placebo effects to occur. This study tested 
whether placebo and cognitive distraction reduce pain through shared or independent 
processes. We crossed an executive working memory task with placebo treatment and 
tested their joint effects on thermal pain perception. A Task x Placebo interaction would 
provide evidence for shared mechanisms, whereas additive effects would imply separate 
mechanisms. Participants (n=33) reported less pain in both Task and Placebo conditions, 
but the reductions were additive, indicating that the executive demands of the task did not 
interfere with placebo analgesia. Furthermore, placebo analgesia did not impair task 
performance. Together, these data suggest that placebo analgesia does not depend on 
active redirection of attention, and that expectancy and distraction can be combined to 
maximize pain relief.  
 
Introduction          
Placebo effects have long been both a nuisance to clinical researchers and a 
therapeutic adjuvant to medical practitioners, and they are thought to affect diverse 
treatment outcomes (Finniss, Kaptchuk, Miller, & Benedetti, 2010). Placebo effects have 
been most commonly documented in pain (Vase, Petersen, Riley, & Price, 2009), and 
placebo analgesia has been demonstrated in both laboratory and clinical contexts 
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(Hrobjartsson & Gotzsche, 2004a). While earlier theories often assumed placebo effects 
simply reflected response bias on the part of participants (Clark, 1969), neuroimaging 
studies have demonstrated that placebo analgesia involves modulation of pain-related 
responses in the brain (Petrovic, Kalso, Petersson, & Ingvar, 2002; Price et al., 2007; for 
review, see Wager & Fields, In press; Wager et al., 2004; Wager et al., 2007) and spinal cord 
(Eippert, Finsterbusch, et al., 2009).  
While much research has focused on whether placebo effects exist, there is almost 
no research on the constituent psychological processes that are required for placebo 
analgesia. In particular, although most current theories emphasize the role of expectations 
(Stewart-Williams & Podd, 2004), it is unclear how expectations relate to other cognitive 
processes such as attention, and what conditions are required for their creation and 
maintenance. One possibility is that reduced expectations of pain might lead one to redirect 
attention away from pain, which is known to have analgesic effects (Buhle & Wager, 2010; 
Legrain et al., 2009; Valet et al., 2004).  If so, expectations might be thought of as a form of 
cognitive control, and executive processes that control attention might be necessary for 
expectations to influence pain. In support of this view, a number of neuroimaging studies 
have reported placebo- and expectancy-related activity in the dorsolateral prefrontal 
cortex (Atlas, Bolger, Lindquist, & Wager, 2010; Eippert, Bingel, et al., 2009; Kong et al., 
2006; Pariente, White, Frackowiak, & Lewith, 2005; Wager et al., 2004; Wager et al., 2007; 
Zubieta et al., 2005), an area known to be involved in executive working memory (Smith & 
Jonides, 1999). Furthermore, fronto-parietal activity predicts the magnitude of placebo 
analgesia (Wager et al., 2011), and measures of frontal activity have been shown to be 
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correlated with both placebo analgesia and tasks requiring executive control (Benedetti et 
al., 2006).   
However, this support is indirect, as the prefrontal cortex is involved in a number of 
cognitive and emotion-related processes not specifically related to control of executive 
attention and working memory. Alternatively, expectations may exert their influences 
primarily though non-cognitive state changes. For example, believing one has been given 
an analgesic may reduce anxiety (Evans, 1985), known to enhance pain (Weisenberg, 
Aviram, Wolf, & Raphaeli, 1984), or such beliefs may engage descending anti-nociceptive 
systems that release pain-reducing neurotransmitters such as endogenous opioids 
(Amanzio & Benedetti, 1999; Wager et al., 2007) without mediation by cognitive processes.  
To directly test whether executive resources mediate placebo analgesia, we 
designed a novel paradigm combining thermal pain, performance of a difficult working 
memory task, and placebo drug treatment. In previous work, we confirmed that performing 
a task that places demands on multiple aspects of executive attention and working memory 
(the N-back; Kane & Engle, 2002; Kirchner, 1958; Smith & Jonides, 1999) substantially 
reduces pain (Buhle & Wager, 2010). Here, we tested whether this cognitive demand 
interferes with analgesia produced by a placebo treatment or whether the two 
manipulations have independent analgesic effects.  When interference is observed between 
two concurrently performed tasks, it may be inferred that those tasks overlap in the mental 
resources they engage, and that the processing capacity of these resources is limited 
(Norman & Bobrow, 1975). We applied this limited resources logic to the relationship 
between attention-driven analgesia caused by the task and expectation-driven analgesia 
caused by the placebo. If the executive attention and working memory processes engaged 
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by the task also support placebo analgesia, then we would expect concurrent performance 
of the task would inhibit placebo analgesia, resulting in an under-additive interaction of 
placebo and task on pain ratings. Alternatively, if placebo analgesia does not involve these 
executive processes, than the effects of task and placebo should be additive, implying 
independent mechanisms.  
 
Method  
Participants. Thirty-three right-handed volunteers (mean age: 27.2 years, range: 18 
years to 55 years; 19 female) completed the experiment. Participants were compensated at 
a rate of $12 per hour, with performance bonuses up to $10 in Session One and $20 in 
Sessions Two and Three. All gave informed consent in accordance with the Columbia 
University Institutional Review Board. 
 
Procedure.  Each participant completed three experimental sessions on separate 
days. In Session One, participants completed 3-back task and thermal calibration 
procedures similar to those reported previously (Buhle & Wager, 2010). The 3-back 
calibration consisted of single block of 16 trials, matched in duration (20.16 s) to those 
used in Sessions Two and Three. Performance was assessed in a signal detection 
framework, using A, a non-parametric measure of target sensitivity (Jun Zhang & Shane T. 
Mueller, 2005). The duration of individual letters in a given trial was reduced if 
participants demonstrated good performance on the previous two trials (A≥.95). The final 
letter duration achieved in the calibration procedure was then used for the remainder of 
the experiment.  
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Thermal pain was delivered using a 16 mm TSA-II NeuroSensory Analyzer (Medoc 
Ltd., Israel). The calibration procedure consisted of 24 trials, matched in duration (20.16 s, 
including 4 s ramp up and 2 s ramp down) to those used in Sessions Two and Three. 
Ratings were made on a 100 unit visual analog scale (VAS) with anchors of “No pain” and 
“Worst imaginable pain” (Price, McGrath, Rafii, & Buckingham, 1983). Trials proceeded in a 
fixed order through 8 skin sites on the left volar forearm. On each trial after the initial 
three, an adaptive procedure was used to predict temperatures corresponding to pain 
ratings of 10, 50, and 90 (henceforth referred to as low, moderate, and high). A linear 
regression model was fit with Temperature as the independent variable and pain as the 
dependent variable. Temperatures whose predicted values corresponded to low, moderate, 
and high pain in were used to determine the temperature applied on the subsequent trial. A 
fixed, counterbalanced order, chosen to maximize predictive power and avoid confounds 
between temperature and time, ensured one application of each of the three levels at each 
of the eight locations. Thus, trial order was always the same, but the temperatures applied 
varied across trials and participants. The final temperature levels derived from this 
procedure were then used for the remainder for of the experiment (for those completing 
the study, low: mean=41.5 °C, SD=1.83 °C; moderate: mean=44.9 °C, SD=1.99 °C) 
Participants were not permitted to advance to Sessions Two and Three if they 
demonstrated an inconsistent relationship between temperature and pain (r2<.7; n=13), if 
they could not perform the task (n=2), or if their calibrated moderate temperature was 
higher than 50 °C; (for safety reasons; n=1). 
Sessions Two and Three consisted of counterbalanced placebo and control sessions 
(Fig. 3.1A). In both sessions, an emollient cream was applied to the skin. In placebo 
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sessions, participants were told this cream contained a powerful analgesic, while in control 
sessions, participants were told it was a non-analgesic control cream. In each session, 
participants then rated pain in 5 blocks of 16 thermal stimuli (Fig 3.1B). In control sessions, 
only moderate pain stimuli were administered. In placebo sessions, low pain stimuli were 
covertly administered in the first block, in order to strengthen the expectation of analgesia. 
The remaining 4 blocks featured moderate stimuli, identical to those applied during the 
control session. In both sessions, during blocks 2 and 4 participants were told to fixate on a 
centrally located cross during stimulation. During blocks 3 and 5, participants performed 
the 3-back task for the duration of stimulation. We chose to compare pain during the 3-
back task to pain during fixation rather than cognitive task with lower executive demand, 
such as a 2-back, in order to maximize our power to detect attention effects and to provide 









Fig. 3.1. Experimental Design. A. Sessions Two and Three. Placebo and Control session order was counterbalanced 






At the end of Session Three, participants were asked to rate the effectiveness of the 
analgesic, (1=“not at all effective”; 10=“extremely effective”). Participants were then asked 
how much they would pay to use the cream in a hypothetical fourth session identical to 
Sessions Two and Three. 
 
 Analyses. In all analyses, session order was used as a between-subjects predictor. 
Only data from the experimental blocks (blocks 2-5) were used. 
A first set of analyses used general linear models (GLMs) to test for effects of Task 
(3-back vs. fixation) and Placebo (placebo vs. control cream) on pain. Model 1A was a 
mixed-effects GLM that included within-subjects effects of Placebo, Task, Placebo x Task, 
and mean-centered trial number and mean-centered trial number squared to model 
habituation/sensitization. Participant was modeled as a random effect. To account for 
variability in mean pain reports and scale use across participants, we first normalized trial-
by-trial ratings within-participant by converting them to z-scores. We calculated Cohen’s d 
to estimate the effect sizes of the main effects and interaction. Because conventional 
statistics cannot provide evidence about the likelihood of the null hypotheses, we used 
Gallistel’s Bayesian procedure on condition averages to estimate the odds in favor of 
accepting the null hypothesis that there was no interaction of Task and Placebo (Gallistel, 
2009). Models 1B through 1D were repeated-measures ANOVAs using condition averages. 
In model 1B, we used the normalized trial-by-trial ratings. In model 1C, to provide an 
alternate method to account for between-participant variability, we used non-normalized 
pain ratings as the outcome variable and each participant’s average pain rating as a 
between-subjects covariate.  To account for the possibility that results might be influenced 
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by non-linear habituation effects across blocks, resulting in higher pain ratings in block 2 
(the first experimental no task block) than in blocks 3-5 (the second experimental no task 
block and both task blocks), models 1D and 1E repeated the analyses of 1B and 1C with 
data from block 2 removed. 
Models 2 and 3 concerned the relationship between Placebo, Pain, and task 
performance. As during the calibration procedure, task performance was assessed using A. 
Only data from blocks in which participants performed the task (blocks 3 and 5) were used 
in these analyses. Model 2 tested whether performance differed as a function of Placebo 
(placebo vs. control runs) using a mixed-effects GLM. As before, we examined the strength 
of evidence for vs. against effects of placebo on task performance using Gallistel’s Bayesian 
procedure (Gallistel, 2009). Model 3 sought to confirm that Pain predicted performance on 
a trial-by-trial basis. First, we normalized pain ratings made by each participant in these 
two blocks by converting them to z-scores. Next, Pain was used as a continuous, within-
subjects predictor in a mixed-effects GLM, with Participant as a random effect, Placebo, 
mean-centered trial number and mean-centered trial number squared as within-subjects 
covariates of no interest, and performance as the outcome variable. 
         
Results 
Participants on average rated the effectiveness of the placebo as 6.6 (SD = 1.9) on 
the 10 point scale, and said they would pay $16.69 (SD = $9.23) to use it again. 
Results from Model 1A confirmed both a main effect of Task, indicating that 
performing the task reduced pain, t(31) = 9.82, p < .001, d = 1.71, and a main effect of 
Placebo, t(31) = 4.10,  p < .001, d = .71, indicating that the placebo treatment also reduced 
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pain. There was no Task x Placebo interaction, indicating that the strength of the placebo 
analgesia was unaffected by the concomitant working memory load, t(31) = -.33,  p = .746, d 
= -.06 (Fig. 3.2A). Gallistel’s Bayesian procedure estimated the odds in favor of the null 
hypothesis that the effects of Task and Placebo were additive to be 6.44 to 1, evidence 
deemed “substantial” in this framework (Gallistel, 2009). Models 1B, 1C, 1D and 1E yielded 
qualitatively identical findings, confirming that these results were not dependent on the 









Fig. 3.2. Pain and performance. A. Both Placebo and Task reduced pain, but there was no interaction. Pain ratings were 
normalized within participants for all experimental blocks (blocks 2-5). B. Working memory task performance was 
identical in the Placebo and Control conditions. In both plots, error bars reflect between-subjects standard error. 
 
Results from Model 2 showed no effect of Placebo on task performance t(31) = -.48, 
p = .63, d = -.08 (Fig. 3.2B). Thus, while placebo analgesia was effective in relieving pain, it 
did not improve task performance. Gallistel’s Bayesian procedure estimated the odds in 
favor of the null hypothesis that the effects of Task and Placebo were additive to be 7.97 to 
1, also deemed “substantial” (Gallistel, 2009). Results from Model 3 showed a significant 
effect of trial-to-trial pain reports on task performance, with higher pain reports predicting 
lower performance, t(31) = -2.42, p < .05, d = -.43. 
          
Discussion          
Recent theories of placebo analgesia have posited a role for executive processes in 
the transformation of expectations into pain relief (Benedetti, 2010; Benedetti et al., 2006; 
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Krummenacher, Candia, Folkers, Schedlowski, & Schonbachler, 2010; Wager et al., 2004). 
However, these theories have largely relied on indirect, neural evidence of DLPFC 
involvement. To test this hypothesis directly, we used a dual task design that 
independently manipulated executive demand and placebo processing. If placebo analgesia 
requires executive attention and working memory, then the performance of a secondary 
task that places high demands on these limited resources should inhibit placebo analgesia. 
We found that both placebo treatment and executive demand reduced pain substantially, 
but their effects were nearly perfectly additive, and Bayesian odds substantially favored the 
null hypothesis of no interference. Furthermore, placebo analgesia had no effect on 
working memory performance, in spite of the fact that performance was sensitive to trial-
by-trial fluctuations in pain. Taken together, these data suggest that placebo analgesia does 
not require executive attention or working memory during pain processing. It is therefore 
unlikely that placebo-related expectations cause relief by altering cognitive processes 
related to the perception and online interpretation of the nociceptive stimuli, for example 
by leading one to redirect attention away from pain (Buhle & Wager, 2010).  
At first blush, these findings might appear to contradict those of Benedetti and 
colleagues (2006), who found that placebo analgesia was reduced in patients with 
Alzheimer’s disease. In that study, the degree of reduction in placebo analgesia was largest 
for those with reduced performance on a frontal lobe task battery and reduced functional 
connectivity between prefrontal and posterior brain sites. Given the profound impairments 
in executive function and frontal atrophy in Alzheimer’s patients, Benedetti and colleagues’ 
findings imply that executive function is involved at some point in the placebo process. 
However, it is also possible that impairments in other processes besides executive 
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attention or working memory, such as long-term memory, might be responsible for the 
failure to recall context information and generate appropriate expectations. Given the 
present results, one plausible explanation is that executive function is important for 
understanding context and constructing meaning during placebo administration (including 
the treatment and delivery of care-related context cues; (Benedetti, 2002; Moerman, 
2002)), but neither executive attention nor working memory is not critical for actively 
maintaining placebo responses once the context has been established.  
Other evidence for the role of executive function in placebo analgesia has been 
suggestive, but still indirect, demonstrating the involvement during placebo of neural 
regions believed to support executive function (Eippert, Bingel, et al., 2009; Kong et al., 
2006; Krummenacher et al., 2010; Pariente et al., 2005; Wager et al., 2004; Wager et al., 
2007; Zubieta et al., 2005). Our results suggest that the involvement of the frontal cortex 
does not imply the engagement of executive attention and working memory in this case. 
The DLPFC is a broad, heterogeneous area containing neurons that subserve a number of 
different functions. The DLPFC-dependent processes that support placebo analgesia may be 
different from the DLPFC-dependent processes that support working memory. In a recent 
analysis of individual differences in placebo analgesia, for example, Wager and colleagues 
(2011) found that DLPFC and superior parietal activity strongly predicted the magnitude of 
placebo analgesia. While the regions involved at first glance appeared to be similar to those 
involved in executive working memory, the placebo-predictive regions did not overlap with 
those derived in a meta-analysis of working memory. Furthermore, a formal test of 
whether placebo analgesia could be predicted by areas involved in working memory vs. 
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those involved in emotional appraisal, including regions in DLPFC in both cases, showed 
that only the appraisal-related regions predicted the magnitude of placebo effects.  
The same ambiguity complicates interpretation of a recent study that found rTMS to 
DLPFC eliminated placebo analgesia (Krummenacher et al., 2010). While their findings, like 
the fMRI studies, implicate DLPFC in placebo analgesia, the study did not test whether the 
TMS stimulation influenced cognitive performance as well.  In a commentary on the work, 
Benedetti (2010) noted that the use of a standard reference system in that study rather 
than individual functional localization of DLPFC also raised the possibility that the effect 
could be due to suppression of adjacent tissue, rather than DLPFC itself. Future TMS studies 
could reduce this ambiguity by demonstrating a selective deficit of executive function at the 
stimulated regions. 
However, while such a demonstration would resolve the ambiguity of localization, it 
would not resolve the question of functional specificity. Swaths of cortex as large as those 
impacted by TMS, or resolved by current neuroimaging techniques, likely support a great 
diversity of functions (Wager, Lindquist, Nichols, Kober, & Van Snellenberg, 2009). Thus, 
the possibility remains that DLPFC is important for placebo analgesia in ways unrelated to 
cognitive control. In fact, extensive evidence suggests that DLPFC regions are also involved 
in the descending opioidergic system mediating placebo analgesia (Eippert, Bingel, et al., 
2009; Wager et al., 2007; Zubieta et al., 2005), which may be relatively independent of 
executive control. The lateral and medial prefrontal cortices project directly to the 
brainstem periaqueductal gray (PAG), a major site of opioid production that modulates 
descending analgesia in the spinal cord, and stimulation of the lateral prefrontal cortex in 
rats evokes analgesia that is reversed by blocking opioids in the PAG (Y. Q. Zhang et al., 
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1997). Thus, the frontal cortex might play a role in affective appraisal and direct regulation 
of brainstem systems that is conceptually and functionally distinct from its role in cognitive 
control. The present findings bear on this hypothesis, because they suggest that placebo 
expectancy-based analgesia, believed to rely on this system, is independent of cognitive 
processes that underlie distraction-based analgesia. This dissociation provides a step 
forward towards establishing the existence of multiple, independent systems for the 
regulation of pain.  
Given that trial-by-trial pain reports predicted task performance, both in these data 
and in previous work (Buhle & Wager, 2010), it is noteworthy that there was no significant 
effect of placebo on performance. Two uninteresting reasons for this finding could be a) 
lack of power and b) insensitivity of performance scores to resource demands, e.g., due to 
floor or ceiling effects (Norman & Bobrow, 1975). Four pieces of evidence argue against 
these alternatives.  First, the effect size was very small and opposite the predicted 
direction, Second, Bayesian odds substantially favored the null hypothesis that placebo 
does not affect performance. Third, performance was calibrated to be well below ceiling, 
and fourth, there existed a negative relationship between pain and performance on a trial-
by-trial basis, demonstrating sensitivity. Thus, these two explanations are less likely than a 
theoretically interesting alternative: That placebo and executive working memory 
distraction may influence different aspects of pain. This interpretation is in line with the 
main findings of the study showing separable effects of placebo and 3-back demand, and 
further suggests that placebo may influence affective aspects of pain that are separable 
from those driven by cognitive elaboration. In addition, it suggests that pain-related 
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cognitive impairment is an interesting functional outcome measure in its own right, which 
may not be affected by the same treatments that influence pain report. 
In addition to helping illuminate the mechanisms that underlie placebo analgesia, 
the results of the present study may also have important clinical implications. If placebo 
and distraction do not rely on overlapping resources, then each provides a separate route 
to pain relief. Combining them may be an efficient way for physicians to maximize 
analgesia without the use of drugs. To further explore this possibility, future work should 
test the same interaction using neural correlates of pain as outcomes.  Such work would be 
important not only for confirming the additive effects on pain reported here, but could also 
reveal important distinctions in how placebos (and related expectancy-based 
interventions) and distraction impact pain. For example, they may exert their influence on 
discrete pain processing stages, on distinct anatomical systems as discussed above, or on 
distinct neurochemical systems. An intriguing possibility is that expectancy effects are 
mediated mainly by medial prefrontal-striatal-brainstem systems, with strong involvement 
of the opioid system and only a peripheral role for frontal and parietal cortices (Atlas et al., 
2010; Wager et al., 2007; Zubieta et al., 2005), whereas the effects of cognitive distraction 
are mediated mainly by direct frontal cortical-somatosensory interactions, without 
engagement of brainstem pain-control systems.  
The present results also raise the possibility that placebo treatments may work in 
patients with impaired executive function. We suggested above that the disrupted placebo 
response observed in Alzheimer’s patients (Benedetti et al., 2006) might reflect the 
importance of executive function or mnemonic processes at the time of placebo induction. 
In some cases, it might be possible to strengthen the induction procedures and thereby 
67 
 
counteract the effect of weakened executive function, or to use conditioning-based 
methods that may not require executive function (Atlas et al., 2010; Colloca et al., 2008; 
Stewart-Williams & Podd, 2004). In other cases, life experiences prior to the development 
of the deficit may provide the needed therapeutic expectation, obviating the need for a 
specific induction procedure (Colloca & Benedetti, 2006). Future research examining the 
placebo response in different patient groups and different treatment contexts will be 
critical to unravel this important clinical issue.  
Finally, it is important to note there exist several alternative explanations for the 
results of the current study. Executive function encompasses a complex set of cognitive 
processes. It remains possible that placebo analgesia does involve executive processes 
other than those required for 3-back task performance. While the present results cannot 
exclude this possibility, we selected the 3-back task because it is complex and places a 
relatively continuous demand on an array of executive functions that load on general fluid 
intelligence, including working memory maintenance in the face of distraction, updating, 
attention shifting and task switching, scheduling of sequences of cognitive operations, and 
monitoring of working memory control (Kane & Engle, 2002; Smith & Jonides, 1999). The 
involvement of multiple executive working memory components is thought to underlie 
findings that training on the N-back task improves general fluid intelligence as assessed by 
Raven’s Advanced Progressive Matrices test (Jaeggi, Buschkuehl, Jonides, & Perrig, 2008). 
Another possible alternative explanation is that placebo analgesia involves the same 
executive processes as the 3-back task, but in the present experiment the combined 
requirements of the placebo and task did not exceed available executive resources. 
However, this alternative is unlikely because task difficulty was titrated for each 
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participant, pushing performance well below ceiling. In addition, the task had a strong 
impact on pain, even relative to other published distraction tasks (see Buhle & Wager, 
2010), suggesting that demand on executive attention and working memory was high and 
continuous during task performance.  
In sum, the present data suggest that placebo analgesia does not require executive 
attention or working memory during the processing of painful stimuli, and that distraction 
and placebo provide two separate routes to pain relief. Previous data suggesting the 
involvement of DLFPC likely reflect the involvement either of adjacent regions or non-
executive functions subserved by the DLPFC. If executive function does play a role in 
placebo analgesia, it is probably limited to the development of appropriate expectations, 






Chapter 4: Distraction but not placebo reduces neural signature of pain 
 
Abstract  
Distraction and placebo analgesia are two effective psychological manipulations for 
alleviating pain. Recently, we showed that distraction and placebo do not appear to rely on 
overlapping cognitive resources, and thus they can be combined to maximize pain relief 
(Buhle, Stevens, Friedman, & Wager, in press). In the present study, we crossed an 
executive working memory task with an expectancy-based placebo treatment in two 
separate fMRI sessions in order to directly compare the neural effects of each method of 
pain relief (n=21). Both distraction and placebo significantly reduced behavioral pain 
reports. Because pain processing involves a complex network of brain regions, we tested 
for neural reductions in two independently-derived, whole-brain, pain-predictive pattern 
maps. The first pattern was generated using machine learning analyses on heat pain data 
from participants run previously in our lab (Wager, Atlas, Lindquist, & Kross, Submitted). 
The second pattern was generated using 'reverse-inference' meta-analysis on 224 pain 
imaging studies (neurosynth.org; Yarkoni, Poldrack, Nichols, Van Essen, & Wager, 2011). 
Pattern-expression analysis with both maps yielded nearly identical results: While 
distraction reduced the neural signature of pain in nearly all participants (95% and 90%, 
respectively, P < .001 in both), placebo reductions were not different from chance (38% 
and 48% of participants). These results call into question whether expectancy-driven 
placebo effects exert widespread effects on pain processing, and provide a way to 
distinguish different brain effects of different types of pain modulatory techniques in a 




Clinicians have long used distraction and placebo as treatments for pain. For 
example, a pediatrician may give a child a shot while telling an engrossing story, and 
internists commonly prescribe antibiotics for viral colds against which they are impotent. 
Despite the profound growth in medical technology in recent decades, these psychological 
manipulations have not disappeared from clinical settings. In fact, virtual reality video 
systems intended to distract patients from ongoing pain have become increasingly 
common in burn units (H. G. Hoffman et al., 2011), and more than 40% of clinicians believe 
placebos have therapeutic effects (Raz et al., 2011).   
Much laboratory research on distraction and placebo has used pain as a model 
system, both because the physiology of pain is relatively well-understood, and because pain 
can be reliably and transiently induced in healthy participants. Experimental studies have 
established that both distraction and placebo effectively reduce pain reports (Buhle & 
Wager, 2010; Vase et al., 2009). Recently, we showed that distraction and placebo do not 
appear to rely on overlapping cognitive resources, and thus they can be combined to 
maximize pain relief (Buhle et al., in press). However, there has long been debate as to 
whether changes in pain reports reflect online changes in the internal experience of pain, 
or other factors, such as response biases (Clark, 1969; Clark & Goodman, 1974; 
Hrobjartsson & Gotzsche, 2003, 2006).   
The advent of neuroimaging promises a possible resolution to this debate. 
Reductions in pain-processing regions as a function of psychological manipulation would 
provide strong confirmation that reduced pain reports reflect veridical changes in pain 
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experience. In the case of distraction, a number of studies have done just that, showing 
reduction in numerous pain processing regions, including medial thalamus (Bantick et al., 
2002; H. G. Hoffman et al., 2011; Remy et al., 2003), anterior insula (Bantick et al., 2002; 
Brooks et al., 2002; H. G. Hoffman et al., 2011; Remy et al., 2003), and ACC (Bantick et al., 
2002; Frankenstein et al., 2001; H. G. Hoffman, Richards, et al., 2004; Remy et al., 2003). 
More limited evidence suggests that distraction may reduce pain-related activity in SI and 
SII (H. G. Hoffman, Richards, et al., 2004; Petrovic et al., 2000). Similarly, neuroimaging 
studies of placebo have consistently reported reduced activity in established pain-
processing regions (Lieberman et al., 2004; Lu et al., 2010; Price et al., 2007; Wager et al., 
2011; Wager et al., 2004). One recent summary identified areas in which at least three 
studies reported at least one coordinate. This analysis found replicated decrease in 
established pain-processing regions such as rostral dorsal anterior cingulate cortex, SII and 
SI, medial thalamus and anterior insula (Wager & Fields, In press). A recent meta-analysis 
found reliable decreases in some overlapping pain-processing regions, including the rostral 
cingulate, thalamus, and anterior and posterior insula, as well as other potential pain-
processing regions, including the mid-cingulate and the basal ganglia (Amanzio, Benedetti, 
Porro, Palermo, & Cauda, in press). 
Although this growing body of work suggests that distraction and placebo may 
indeed dampen activity in pain processing regions, caution is still warranted. To date, all 
studies claiming decreases have done so on the basis of activation peaks in putative pain 
processing regions. However, pain is a complex experience involving many brain regions, 
and it may involve both increases and decreases in regional activity. Furthermore, nearly 
all cortical regions involved in pain processing are likely also involved in other processes. 
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Thus, it is unclear if the scattered peaks reported previously reflect widespread neural 
reductions in pain processing, reductions in a limited number of pain processing areas, 
reductions in non-pain related processes, or even chance findings and publication bias.    
In the present study, we crossed an executive working memory task with an 
expectancy-based placebo treatment in two separate fMRI sessions in order to obtain 
measures of both distraction and placebo analgesia within the same participants. Next, we 
calculated summary measures of neural activity in each condition using pain-predictive 
pattern maps derived from independent samples. Our results provide the first tests of 
whether distraction and placebo lead to overall reductions in the neural signature of pain.  
          
Method 
Participants. Thirty-one right-handed volunteers (mean age: 27.8 years, range: 18 
years to 45 years; 14 female) completed the experiment. However, scanner errors 
rendered imaging data unusable for 10 participants. Additionally, behavioral data was lost 
for 9 participants, including 6 of the participants with usable imaging data. To maximize 
sample size, behavioral analyzes were conducted on all 22 participants with behavioral 
data (mean age: 27.5 years, range: 18 years to 45 years; 9 female), and imaging analyses 
were completed on 21 participants (mean age: 27.9 years, range: 18 years to 45 years; 10 
female). Participants were compensated at a rate of $12 per hour, with performance 
bonuses up to $10 in Session One and $20 in Sessions Two and Three. All gave informed 




Procedure. Each participant completed three experimental sessions on separate 
days. In Session One, participants completed 3-back task and thermal calibration 
procedures similar to those reported previously (Buhle & Wager, 2010). The 3-back 
calibration consisted of a single block of 16 trials, matched in duration (20.16 s) to those 
used in Sessions Two and Three. Performance was assessed in a signal detection 
framework, using A, a non-parametric measure of target sensitivity (Jun Zhang & Shane T. 
Mueller, 2005). The duration of individual letters in a given trial was reduced if 
participants demonstrated good performance on the previous two trials (A≥.95). The final 
letter duration achieved in the calibration procedure was then used for the remainder of 
the experiment.  
Thermal pain was delivered using a 16 mm TSA-II NeuroSensory Analyzer (Medoc 
Ltd., Israel). The calibration procedure consisted of 24 trials, matched in duration (20.16 s, 
including 4 s ramp up and 2 s ramp down) to those used in Sessions Two and Three. 
Ratings were made on a 100 unit visual analog scale (VAS) with anchors of “No pain” and 
“Worst tolerable pain” (Price et al., 1983). We explained that a rating of 100 should be 
comparable to coffee cup so hot that, if it were any hotter, he or she would no longer be 
able to hold it. Trials proceeded in a fixed order through 4 skin sites on the left volar 
forearm. Six temperatures (44.5 °C, 45.3 °C, 46.1 °C, 46.9 °C, 47.7 °C, 48.5 °C) were used. A 
fixed, counterbalanced order, chosen to maximize predictive power and avoid confounds 
between temperature and time, ensured one application of each of the six levels at each of 
the four locations. Thus, trial order and temperature levels used in the calibration were the 
same for all participants. Following the calibration procedure, a linear regression model 
was fit with Temperature as the independent variable and pain as the dependent variable. 
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Temperatures whose predicted values corresponded to 10 and 50 (henceforth referred to 
as low and moderate pain were then used for the remainder for of the experiment (for 
those completing the study, low: mean=45.5 °C, SD=.7 °C; moderate: mean=47.1 °C, SD=.8 
°C) Participants were not permitted to advance to Sessions Two and Three if they 
demonstrated an inconsistent relationship between temperature and pain (r2<.5; n=12), if 
they could not perform the task (n=7), or if their calibrated moderate temperature was 
above our safety cut-off (>50 °C; n=5). 
Following the thermal and task calibration procedures, participants underwent a 
placebo induction procedure similar to those we have used previously (Buhle et al., in 
press). First, participants rated a single moderate stimulation on each of the four volar 
forearm locations. Next, the experimenter applied to the skin an emollient cream, which 
participants were told contained a powerful analgesic. Following cream application, 
participants were asked to wait ten minutes for the cream to take effect. After the wait, 
participants rated a single low stimulation on each of the four volar forearm locations. 
Importantly, participants were told that these stimulations were at the same temperature 
as those they experienced before the cream was applied.  
Finally, participants performed one practice block of the task similar to those used 
in Sessions Two and Three. The block consisted of 9 trials, each lasting 20.16 s (Fig. 4.1). 
Each of three trials types (Watch, Left-Right, and 3-Back) appeared three times in 
pseudorandom, counterbalanced order. On Watch trials, participants were told to simply 
maintain fixation on a centrally-presented crosshair. On Left-Right trials, participants were 
asked to press the left mouse button when an “L” appeared and the right button when an 
“R” appeared. On 3-Back trials, participants were asked to press one button whenever a 
75 
 
letter shown was the same as the letter presented three prior, and the other button when 
the letter was not the same. The letter duration achieved in the calibration procedure was 
used for both Left-Right and 3-Back trials. Furthermore, the sequence of each trial of one 
type was tethered to the sequence of a trial of the other type, such that correct responding 
would entail an identical sequence of button presses. Temperatures were also applied for 
the duration of each trial. To maintain the placebo rouse, low temperatures were used 
throughout the block. Participants rated the temperatures following each trial. 
 
 
Fig. 4.1.  Experimental design for Sessions Two and Three. Placebo and Control session order was counterbalanced 
between participants. Blocks 2-5 were identical in both conditions.  
 
Sessions Two and Three consisted of counterbalanced placebo and control sessions. 
After practicing the task, subjects were placed in a 3-Tesla Phillips scanner. In both 
sessions, the same emollient cream used during Session One was then applied to the skin. 
While in placebo sessions participants were told this cream contained the analgesic used 
previously, in control sessions participants were told it was a non-analgesic control cream. 
Following cream application, two five minute resting-state functional scans were acquired. 
Participants then performed 6 blocks of the task. In control sessions, only moderate pain 
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stimuli were administered. In placebo sessions, low pain stimuli were covertly 
administered during the first block, in order to strengthen the expectation of analgesia. The 
remaining 5 blocks featured moderate stimuli, identical to those applied during the control 
session. All blocks contained three trials of each type (Watch, Left-Right, and 3-Back) in 
pseudorandom, counterbalanced order. For a given participant, the same trial order was 
used in both the placebo and control sessions. In addition, the same order of correct and 
incorrect responses was maintained across the two sessions, though the actual letters used 
varied.  
At the end of Session Three, participants were asked to rate the effectiveness of the 
analgesic, (1=“not at all effective”; 10=“extremely effective”). Participants were then asked 
how much they would pay to use the cream in a hypothetical fourth session identical to 
Sessions Two and Three. 
 
Functional MRI Acquisition and Preprocessing.  Whole-brain functional data 
were acquired in 42 axial slices (3 × 3 × 3 mm voxels) with a T2*-weighted gradient echo 
sequence (repetition time (TR) = 2,000 ms, echo time (TE) = 20 ms, flip angle = 72, field of 
view (FOV) = 22.4 cm). Structural data were acquired with an MP-RAGE SENSE sequence (1 
× 1 × 1 mm, flip angle = 8, FOV = 25.6 cm x 20 cm). 
Functional scans were preprocessed with SPM5, using slice-time correction, motion 
correction, spatial normalization to the MNI space, and spatial smoothing using an 8-mm 
full-width at half-maximum Gaussian kernel. To perform spatial normalization, we: 1. 
Coregistered the two structural images and computed a mean structural image; 2. 
Coregistered the functional images from the two sessions and computed a mean functional 
77 
 
image; 3. Coregistered the mean structural and functional images; 4. Normalized the mean 
structural image to the SPM template using the “unified segmentation” algorithm; 5. 
Applied the normalization parameters to the functional images, and sampling the resulting 
images at 3 × 3 × 3-mm resolution. 
 
 Analyses. In all analyses, Session Order (placebo or control first) was used as a 
between-subjects predictor, and Participant was modeled as a random effect. Only data 
from the experimental blocks (blocks 2-6) were used. Since we had directional hypotheses 
based on prior results, all tests were one-tailed.  
Behavioral data were analyzed with a mixed-effects GLM that included within-
subjects effects of Placebo, Task, Placebo x Task. 
For the imaging data, subject-level statistical analyses were conducted using the 
general linear model framework implemented in SPM8. Boxcar regressors, convolved with 
the canonical hemodynamic response function, modeled as epochs the three trial types, the 
trial instructions, and the rating periods. Voxel-wise statistical parametric maps 
summarizing differences between trial types were calculated for each participant 
participant and then entered into robust-regression, random-effects group analyses. Group 
analysis maps and tables were generated by identifying clusters consisting of at least 5 
voxels, each with p<.001. For the maps, contiguous voxels with p<.05 were then added to 
these clusters to aid with visualization.  
For the pattern-expression analysis, we used three independently-derived, whole-
brain pattern maps. The first pattern map was generated using machine learning analyses 
on heat pain data from participants run previously in our lab (Fig. 4.2A; Wager et al., 
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Submitted). The second map was generated using ‘reverse-inference’ meta-analysis on 224 
pain imaging studies (neurosynth.org; Yarkoni et al., 2011). The two pain-predictive maps 
were somewhat correlated (r=.29). The third map was also generated using ‘reverse-
inference’ meta-analysis, but on 363 working memory imaging studies.  The working 
memory map showed small, negative correlations with each pain map (r=-.19 and -.06, 
respectively). For each map, pattern-expression was calculated as the cross-product of the 
weights in the mask and the condition beta maps for each participant (PExp = Xw, where w 
is mask weights and X is a matrix with voxel-wise beta weights, organized with images in 
rows and voxels in columns). We then performed repeated-measures ANOVAs on these 






Fig. 4.2. Neural signature of pain. A. Thresholded machine learning pattern map. B. Machine learning pain pattern 
expression as a function of Task and Placebo. C. Neurosynth pain pattern expression as a function of Task and Placebo.  In 
both pattern expression analyses, Task reduced the neural signature of pain, but Placebo did not. Only data from the 
experimental blocks (2-6) were included, and error bars reflect between-subjects standard error.  
    
Results   
Participants on average rated the effectiveness of the placebo as 6.5 (SD = 1.8) on 
the 10 point scale, and said they would pay $11.70 (SD = $6.40) to use it again.  
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The behavioral analysis confirmed both a main effect of Task, indicating that 
performing the task reduced pain, t(20) = 6.02, p < .0001, d = 1.28, and a main effect of 
Placebo, t(20) = 1.73,  p < .05, d = .37, indicating that the placebo treatment also reduced 
pain. There was also a Task x Placebo interaction, t(20) = 2.20,  p < .05, d = .47 (Fig. 4.3).  
 
Fig. 4.3.  Pain ratings as a function of Task and Placebo. Both Task and Placebo reduced pain. Only data from the 
experimental blocks (2-6) were included, and error bars reflect between-subjects standard error. 
 
A voxel-wise group contrast of three-back trials greater than watch trials, collapsing 
across placebo conditions, revealed positive clusters in regions associated with executive 
attention and working memory, including DLPFC, dorsal ACC (dACC), dorsal anterior 
insula, premortor cortex, and parietal cortex, and negative clusters in regions associated 
with pain, including SII,  rostral ACC (rACC), and middle and posterior insula (Fig. 4.4, Table 
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4.1). A group contrast of three-back trials greater than left-right trials, collapsing across 
placebo conditions, revealed a nearly identical pattern of increases in regions associated 
with executive working memory and attention, and decreases in regions associated with 
pain (Fig. 4.5, Table 4.2). A group contrast of control trials greater than placebo trials, 
collapsing across task types, revealed positive clusters in regions including anterior and 
posterior insula, left dorsal PFC, anterior PFC, and dorsomedial parietal cortex, and 
negative clusters in regions including parietal cortex, occipital cortex, and  (Fig. 4.6, Table 
4.3). A group contrast of control trials greater than placebo trials that included only the 
watch task trials revealed positive clusters in regions including dorsal anterior insula, 
precuneus, and parietal cortex, and negative clusters in regions including dorsomedial PFC 








Table 4.1.  Group contrast of three-back greater than watch trials, collapsing across placebo conditions. . Only clusters 












Size in Voxels 
 
Size in mm3 
 
T-statistic  
1 -6 -28 -6 3120 24960 22.93 
2 -38 -74 -8 2268 18144 14.78 
3 -2 -12 -24 12 96 5.04 
4 30 -72 6 2988 23904 11.19 
5 -30 24 0 152 1216 7.37 







4 20 160 4.55 
12 57 456 4.64 
9 -28 -18 44 8524 68192 20.77 
10 -44 6 -14 3325 26600 -18.47 
11 14 -36 4 15061 120488 -16.96 
12 44 38 -2 1003 8024 -8.41 
13 -64 -36 -8 256 2048 -7.47 
14 -2 50 20 7956 63648 -15.45 
15 14 10 -10 9 72 -4.3 
16 66 -38 -2 172 1376 -8.07 
17 68 -24 -6 9 72 -5.19 
18 36 6 10 64 512 -5.57 
19 -52 -30 10 7 56 -4.39 
20 -52 -62 30 1313 10504 -10.85 
21 50 -64 26 1020 8160 -9.8 
22 -16 -40 18 7 56 -4.56 
23 36 -24 52 380 3040 -6.25 










Table 4.2.  Group contrast of three-back greater than left-right trials, collapsing across placebo conditions. . Only clusters 











Size in Voxels 
 
Size in mm3 
 
T-statistic  
1 -20 -68 26 7480 59840 14.07 
2 -32 26 0 299 2392 9.21 
3 34 26 0 119 952 5.27 
4 30 -76 2 5 40 4.73 
5 -28 12 42 3309 26472 11.44 







24 30 240 6.46 
32 204 1632 5.91 
9 28 6 50 274 2192 10.73 
10 -4 36 42 5 40 6.06 
11 -44 -12 -4 4582 36656 -9.8 
12 50 -18 4 7780 62240 -14.62 
13 24 12 -18 5 40 -4.41 
14 0 50 12 6282 50256 -13.84 
15 42 34 -12 275 2200 -7.41 
16 32 -36 -12 13 104 -5.14 
17 -68 -38 -4 34 272 -5.27 
18 -2 -38 30 5005 40040 -10.83 
19 -50 -62 30 661 5288 -7.59 
20 24 -16 28 50 400 -12.98 
21 22 22 32 7 56 -7.53 
22 -32 -20 46 52 416 -5.01 







58 45 360 -5.35 









Table 4.3.   Group contrast of control greater than placebo trials, collapsing across task types. Only clusters with at least 5 











Size in Voxels 
 
Size in mm3 
 
T-statistic  
1 46 -14 -2 5 40 4.12 
2 -62 -56 10 5 40 4.54 
3 -22 50 14 38 304 5.84 
4 -52 22 12 6 48 5.05 
5 26 60 20 5 40 4.26 







50 20 160 4.8 
60 28 224 7.17 
9 4 6 18 5 40 -5.29 
10 38 -62 22 7 56 -4.73 
11 -18 -64 24 7 56 -5.4 










Table 4.4.   Group contrast of control greater than placebo trials, watch trials only. . Only clusters with at least 5 
contiguous voxels at p<.001 were included.  
 
The first pattern-expression analysis, using the machine learning pattern maps 
derived from a previous heat pain study in our lab, confirmed a main effect of Task, 
indicating that performing the task reduced pain expression, F(2, 100) = 49.01, p < .001, 
but found no main effect of Placebo, F(1, 100) = .002,  p = .962, indicating that the placebo 
treatment had no effect on the expression of the neural pain pattern. The summary pattern 
expression values were higher in the watch condition than the three-back in 95% of 
participants, higher in the watch condition than the left-right condition in 71% of 
participants, and higher in the left-right condition than the three-back condition in 95% of 
participants. The summary pattern expression values were higher in control condition than 
the placebo in 52% of participants, close to chance. There was no Task x Placebo 
interaction, indicating that the strength of the distraction-induced analgesia was unaffected 










Size in Voxels 
 
Size in mm3 
 
T-statistic  
1 -30 24 -14 20 160 5.8 
2 -46 -82 2 37 296 8.59 
3 12 -76 -2 9 72 4.33 
4 -38 30 0 18 144 9.56 
5 -26 22 0 5 40 6.23 







28 22 176 6.26 
38 25 200 8.26 
9 26 -44 8 7 56 -4.61 
10 -8 36 40 19 152 -5.86 
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Nearly identical results were obtained using the second pattern map, generated 
from neurosynth.org, with a main effect of Task, F(2, 100) = 32.79, p < .001, but no main 
effect of Placebo, F(1, 100) = .05,  p = .816, and no Task x Placebo interaction, F(2, 100) = 
.08,  p = .924 (Fig. 4.2C). The summary pattern expression values were higher in the watch 
condition than the three-back in 90% of participants, higher in the watch condition than 
the left-right condition in 62% of participants, and higher in the left-right condition than 
the three-back condition in 90% of participants. The summary pattern expression values 
were higher in control condition than the placebo in 48% of participants, close to chance.   
The third pattern-expression analysis, using the working memory pattern map 
generated from neurosynth.org, confirmed a main effect of Task, indicating that performing 
the task increased working memory expression, F(2, 100) = 82.26, p < .001, but found no 
main effect of Placebo, F(1, 100) = .595,  p = .442, indicating that the placebo treatment had 
no effect on the expression of the working memory pattern. The summary pattern 
expression values were higher in the three-back condition than the watch condition in 
100% of participants, and higher in the three-back condition than the left-right condition in 
95% of participants, but higher in the left-right condition than the watch condition in only 
48% of participants, close to chance. The summary pattern expression values were higher 
in placebo condition than the control in 43% of participants, also close to chance. There 
was no Task x Placebo interaction, indicating that the strength of the distraction-induced 
analgesia was unaffected by the placebo manipulation, F(2, 100) = .27,  p = .77 (Fig. 4.2B).  
Discussion          
Although both distraction and placebo lowered pain ratings, only distraction 
reduced the neural signature of pain throughout the brain. We obtained nearly identical 
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results using two different pattern maps, generated using different methods and entirely 
different data sets. 
The results are surprising, given that previous placebo research has found reliable 
activated reductions of activity in pain-processing regions. One possible explanation is that 
the lack of neural placebo effects in the present experiment reflects a critical design flaw of 
some kind. Given that we obtained clear reductions in pain processing as a function of 
distraction, such a flaw cannot be attributed to the stimulation paradigm, or the quality of 
the fMRI data. It might be the case that the placebo manipulation in this study was 
insufficient to produce strong effects. Consistent with this possibility, we did not see 
placebo-induced increases in PFC similar to those that have been reported previously 
(Wager & Fields, In press). We did see some placebo-induced reductions similar to those 
that have been previously in regions including the ACC and anterior insula, but only during 
the watch trials.  
However, the design we used is very similar to one we have previously shown to 
produce placebo analgesia, and it is comparable to many others used commonly in the 
literature. Furthermore, the placebo effectively reduced pain reports, although the effect 
size was smaller in the present compared to the previous study (d = .37 and .71, 
respectively). It is also possible that the difference between our behavioral and neural 
results reflects the overlapping but not identical participants in each analysis. However, 
each analysis contained a similar number of participants (22 and 21 in the behavioral and 
imaging analyses, respectively), so different sample sizes probably did not drive the 
difference in results. At the very least, the present results show that is possible to obtain 
reduced placebo effects without a concomitant reduction in the neural signature of pain. Of 
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course, it is possible that the brain is a considerably less sensitive measure of placebo than 
self-report. If so, our study may have had sufficient power to detect a behavioral effect, but 
insufficient power to detect a neural effect. The best way to address this possibility will be 
for other groups to perform similar analyses on previously collected placebo data. This 
should be relatively easy to do, as one of the pattern maps we used is freely available 
online.  
In the present study, we used an expectancy-based placebo manipulation. Although 
we did expose participants to trials with covertly lowered temperature, these trials were 
intended only to enhance the expectation, not to induce a true conditioned response. 
Future research should test whether conditioning-based placebo treatment reduces the 
neural expression of these pain-predictive patterns. 
It is worth noting that in the present data we observed an interaction between Task 
and Placebo in the behavioral pain reports. This result appears to conflict with a previous 
study (n=33) in which we found no interaction between these factors. The paradigms were 
very similar in the two experiments, and the limited differences between the two 
paradigms, such as the present use of a fixed temperature calibration, the MRI context, or 
the addition of the left-right condition, seem unlikely to explain a change in the interaction. 
As can be seen in Fig. 4.3, the interaction was driven by under-additive differences in the 
three-back and left-right conditions. A pattern like this is often produced when participants 
cannot or will not rate stimuli below a certain level—a floor effect. Consistent with this 
possibility, 8 of the 22 participants in the behavioral analysis had average ratings below 3 
on the 100 point scale in at least one condition. Furthermore, no floor effect would be 
expected in the pain pattern expression data, and in those analyses we observed no 
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interaction between Task and Placebo. For these reasons, we believe that the previously 
reported lack of interaction most likely reflects the true pattern of pain experience. 
In sum, these results suggest that while distraction effectively dampens pain 
processing in the brain, expectancy-driven placebo effects may not exert widespread 
effects on pain processing. More generally, this approach provides a way to distinguish 
different brain effects of different types of pain modulatory techniques in a principled, a 
priori fashion. We hope our results will encourage other groups to perform similar 
analyses, both on novel and existing data, so that we may more clearly identify 
psychological and non-psychological manipulations that effectively reduce the neural 





Chapter 5: General Discussion 
 
The present series of experiments examined the neural and cognitive processes that 
constitute distraction and placebo analgesia. All three studies used the limited resources 
logic that when tradeoffs are observed between two concurrently performed tasks, it may 
be inferred that the tasks overlap in the mental resources they engage (Norman & Bobrow, 
1975). Result from Study 1 suggested that overlapping cognitive resources are involved in 
both pain and executive attention and working memory. Study 2 provided evidence that 
these same executive attention and working memory resources are not involved in placebo 
analgesia, and that placebo analgesia and distraction constitute separate routes to pain 
relief. Study 3 tested whether distraction and placebo analgesia reduce expression of a 
whole-brain, pain-predictive activity pattern. We found that while both distraction and 
placebo reduced pain reports, only distraction led to a widespread reduction of the neural 
signature of pain.  
A great deal of work remains to be done to understand the neural mechanisms 
underlying distraction-based analgesia. As reviewed in Chapter 1, converging evidence 
supports the hypothesis that when performing a demanding cognitive task concurrent with 
pain experience, frontal regions invoke PAG-mediated descending inhibition. Future work 
should seek additional support for this extraordinary hypothesis, by using brainstem-
specific imaging techniques to confirm the involvement of other crucial brainstem regions 
in the descending pathway, such as the rostroventromedial medulla (RVM), as well as 
reduced activity in the spinal cord, as has been done recently in placebo analgesia (Eippert, 
Finsterbusch, et al., 2009). If distraction-based analgesia relies on similar descending 
95 
 
mechanisms as placebo analgesia, these mechanisms may also be opioid-mediated. Future 
work should examine whether the opioid antagonist naloxone disrupts the analgesic effect 
of distraction, as it does in placebo (Grevert, Albert, & Goldstein, 1983).    
The pattern expression approach to assessing the neural signature of pain used in 
Study 3 offers an exciting new method for testing the effects of pain modulatory 
techniques. As can be seen in sections of the Introduction that discuss the neuroanatomy of 
distraction and placebo, many previous studies have reported reductions in pain 
processing areas. However, not all studies reported reductions, and among those that did 
report reductions, there were differences in the specific regions observed. The pain matrix 
is vast. Not only is it comprised of many regions, but some of these regions are quite large, 
leading to a difficult to quantify multiple comparisons problem. Thus, it is possible that 
chance alone is responsible for the presumed pain processing reductions that have been 
reported. To make matters worse, the borders cannot be perfectly delineated. It is likely 
that some of the activations believed to represent pain activity in fact reflect activity in 
adjacent, non-pain related areas. Finally, most pain processing regions are known to be 
involved in non-pain processes as well. Reduced processing observed in a limited set of 
pain regions might reflect a real reduction in pain processing, but it also might reflect a 
change in activity unrelated to pain.  
The pattern expression approach at least partially overcomes these concerns by 
providing a summary value that reflects pain activity across the brain. To our knowledge, 
Study 3 represents the first use of such a technique in testing pain modulation approaches.  
As reported in Chapter 4, we found widespread reductions in the neural signature of pain 
as a function of distraction, but no differences as a function of placebo. It is quite possible 
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that our design lacked sufficient power to detect the influence of the placebo effect on the 
neural signature of pain. To answer this question, we hope to extend these analyses soon to 
other datasets that have been previously collected by our lab, and we hope other groups 
will perform similar analyses. If these results do in fact hold across multiple datasets, it 
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